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Zusammenfassung 
 
Das abundante kernlokalieserte RNA-Bindeprotein hnRNP L (heterogeneous 
nuclear ribonucleoprotein L) erfüllt eine Reihe von verschiedenen Aufgaben, die im 
Cytoplasma beziehungsweise im Zellkern stattfinden, u.a. Export von Intron-freien 
mRNAs, IRES-vermittelte Translation, mRNA-Stabilität und Regulation von 
alternativem Spleißen. Es ist bekannt, dass hnRNP L seine eigene Expression auf 
der Ebene des alternativen Spleißens reguliert, ein Prozess, der als Autoregulation 
bezeichnet wird. HnRNP L bindet neben CA-Wiederholungssequenzen auch CA-
reiche Sequenzen. Ein bekanntes Paralog von hnRNP L, hnRNP L-like (LL), wird 
gewebespezifisch exprimiert. Bisher konnte gezeigt werden, dass hnRNP LL in 
Abhängigkeit von der T-Zell-Aktivierung das alternative Spleißmuster von CD45 
reguliert. 
Die beiden Proteine, hnRNP L und hnRNP LL, zeigen bei etwa gleicher Größe (L: 
558 Aminosäuren vs. LL: 542 Aminosäuren) 58% Übereinstimmung in ihrer 
Aminosäuresequenz. Beide besitzen vier klassische RNA-Erkennungsmotive, 
sogenannte RRMs, aber die Glycin-reiche Region von hnRNP L ist in hnRNP LL 
weniger stark ausgeprägt, und die Prolin-reiche Region fehlt vollständig. 
Um die Funktion der einzelnen Domänen beider Proteine im Detail zu untersuchen, 
habe ich eine Reihe von Proteinvarianten kloniert. Bei einigen wurden Teile der 
Proteinsequenz entfernt, während bei anderen einzelne oder mehrere Aminosäuren 
substitutiert wurden. 
Zunächst habe ich die Bindungseigenschaften von hnRNP L und hnRNP LL sowie 
ihrer Varianten an CA-Wiederholungssequenzen bzw. CA-reichen Sequenzen 
mittels EMSA (electrophoretic mobility shift assay) und Filterbindungsexperimenten 
untersucht. Ich konnte zeigen, dass für hnRNP L eine Kombination von zwei RNA-
Bindedomänen, entweder RRMs 1 und 2 oder RRMs 2 und 3, notwendig und 
ausreichend ist, um CA-Wiederholungssequenzen mit hoher Affinität zu binden. Im 
Gegensatz dazu werden alle vier RRMs für eine hoch-affine Bindung von CA-
reichen Sequenzen benötigt. Im Falle von hnRNP LL sind allerdings für die Bindung 
sowohl von CA-Wiederholungssequenzen als auch von CA-reichen Sequenzen alle 
vier RRMs nötig. Mutationsanalysen für hnRNP L haben zudem gezeigt, dass 
RRM2 hauptverantwortlich für die RNA-Bindungsspezifität sowie Bindungsaffinität 
ist. 
EMSA und Gelfitrationsexperimente zeigen, dass hnRNP L mindestens zwei high-
score Bindemotive benötigt, welche durch einen kurzen Abschnitt von 7 bis 10 
Nukleotiden Länge getrennt sein müssen, um die RNA fest binden zu können.  
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Des Weiteren wurden die unterschiedlichen hnRNP L Varianten auf ihre 
regulatorische Aktivität in in vitro Spleißkomplementierung getestet. Als Substrat 
diente ein SLC2A2 Minigen-Konstrukt, welches in hnRNP L-depletiertem 
Kernextrakt inkubiert wurde. Durch Zugabe der verschiedenen Proteinvarianten 
konnte ich zeigen, dass nur das komplette Wildtyp-Protein und keine der verkürzten 
Mutanten eine Repressorfunktion bei der Regulation des alternativen Spleißens 
ausübt. 
Außerdem konnte gezeigt werden, dass die Interaktion zwischen den RRMs 3 und 
4 des hnRNP L Proteins für die Bindung CA-reicher Sequenzen und die 
Spleißregulation wichtig ist. 
Zusammenfassend ist zu sagen, dass aufgrund der vorliegenden Ergebnisse alle 
vier RRMs von hnRNP L nötig sind, um die volle Repressor-Funktion des Proteins 
bei der Regulation von alternativem Spleißen zu entfalten, während die beiden N-
terminalen RRMs für die stabile Bindung zu CA-repetitiver RNA ausreichend sind. 
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Summary 
 
The heterogeneous nuclear ribonucleoprotein L (hnRNP L), an abundant nuclear 
RNA-binding protein, plays both nuclear and cytoplasmic roles in mRNA export of 
intronless genes, IRES-mediated translation, mRNA stability and alternative splicing 
regulation. Recently, it was reported that hnRNP L autoregulates its own expression 
on the level of alternative splicing. HnRNP L protein recognises CA-repeat as well 
as CA-rich clusters. HnRNP L-like (LL) protein is a paralog of hnRNP L, whose 
expression is upregulated in a tissue-specific manner. It was shown that hnRNP LL 
regulates alternative splicing of CD45 exon 4 upon T-cell activation. 
HnRNP L and hnRNP LL share 58% overall amino acid identity and have similar 
sizes (558 vs. 542 amino acids). Both proteins contain four classical RNA 
recognition motifs (RRMs). The glycine-rich region of hnRNP L is less pronounced 
in hnRNP LL, and the proline-rich region of hnRNP L is absent in hnRNP LL. 
To investigate the role of individual domains in hnRNP L and hnRNP LL protein 
function, I created a series of deletion derivatives and mutants with one or several 
amino acid substitutions in individual RNA-binding domains. 
First, I analysed the RNA-binding properties of the full-length and deletion 
constructs of hnRNP L and LL by EMSA (electrophoretic mobility shift assay) and 
filter binding assay. Two substrates were used: CA-repeat and CA-rich RNAs. I 
demonstrated that the combination of two RNA-binding domains of hnRNP L 
(RRMs 1/2 and 2/3) is both necessary and sufficient for high-affinity binding to CA-
repeat RNA. In contrast, the high-affinity binding of hnRNP L to CA-rich RNA 
requires all four RRMs. In the case of hnRNP LL all four RRM domains are required 
for high-affinity binding to both substrates. Mutational analysis revealed that hnRNP 
L RRM2 is a major determinant for RNA-binding specificity and affinity. 
EMSA in combination with gel filtration of protein-RNA complexes indicated that 
hnRNP L requires at least two high-score binding motifs, separated by a short 
spacer (7-10 nucleotides) to bind tightly to the RNA. 
Second, hnRNP L mutant derivatives were tested for alternative splicing activity, 
using a SLC2A2 minigene construct and hnRNP L depleted nuclear extract. I 
demonstrated that only full-length protein and not the truncated mutant proteins 
could function as a repressor in regulation of alternative splicing. 
In addition, a specific role of inter-domain interaction between RRMs 3 and 4 in CA-
rich RNA binding and function of hnRNP L as a splicing repressor was uncovered. 
In sum, my results suggest that the presence of all four RRMs is essential for 
splicing repressor activity of hnRNP L, whereas the two N-terminal RRMs are 
sufficient for tight association with CA-repeat RNA. 
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1. Introduction 
 
 
The studying of several eukaryotic genomes demonstrated that the large proteomic 
complexity is achieved with a limited number of protein-coding genes. These 
findings reveal the importance of post-transcriptional mechanisms in generation of 
protein diversity. Eukaryotic messenger RNA (mRNA) undergoes a series of 
processing events: capping of the 5’ end, polyadenylation of the 3’ end, splicing, 
and editing of individual nucleotides in the RNA. 
Splicing plays one of the most important roles in the generation of protein isoforms 
from a limited number of genes. Alternative splicing is the inclusion of alternative 
exons or introns from the pre-mRNAs into the mature mRNA. A recent study of the 
human genome reveals that 95% of all multi-exon genes undergo alternative 
splicing (Wang et al., 2008). Therefore, alternative splicing allows the existence of 
large proteomic complexity based on a limited number of genes. 
The correct post-transcriptional RNA processing steps are regulated by RNA-
binding proteins (RBPs). Eukaryotic cells encode a large number of RBPs 
(thousands in vertebrates), and each protein has unique RNA-binding activity and 
protein-protein interaction characteristics (Glisovic et al., 2008). The activity of 
RBPs is mediated by a relatively small number of RNA-binding scaffolds whose 
properties are further modulated by auxiliary domains. 
 
1.1 Splicing of pre-mRNA 
 
 
Eukaryotic genes are composed of non-coding sequences (introns) and coding 
regions (exons). The average human gene contains 8 introns with an average 
length of 3,4 kb, interspersed by exons that average less than 300 bp in length 
(Sakharkar et al., 2004). The largest known gene is the human dystrophin gene, 
which has 79 exons spanning at least 2,300 kilobases (kb) (Pozzoli et al., 2002). 
Splicing is a process of removing the introns from pre-mRNA. One of the main 
challenges during pre-mRNA splicing is the reliable determination of the exon/intron 
boundaries. 
There are several conserved intronic sequence elements essential for exon 
definition: 5’ splice site (AG/GURAGU), 3’ splice site (CAG/G), branchpoint 
sequence (YNYURAC), which is typically located within 30 to 50 nucleotides 
upstream of the 3’ splice site, and an immediately adjacent stretch of pyrimidines 
1. Introduction 
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termed polypyrimidine tract (Green et al., 1986; Lim and Burge, 2001; Sheth et al., 
2006) (Figure 1.1). 
Introns with GT-AG splice sites are called U2-type or major introns. A novel class of 
eukaryotic nuclear pre-mRNA introns was found on the basis of their unusual splice 
sites (Hall and Padgett, 1994). These introns contain AT and AC dinucleotides at 
the 5’ and 3’ splice sites, respectively. This type of introns was named U12-type or 
minor introns. U12 introns are recognised by a different spliceosome and excised 
through identical chemical pathway (Hall and Padgett, 1996; Tarn and Steitz, 
1996a, 1996b; Tarn and Steitz, 1997; König et al., 2007). U12 introns occur in the 
total population of introns at a frequency of about 1/5000 to 1/10000 (Burge et al., 
1998; Levine and Durbin, 2001). All known examples of U12-dependent introns 
occur in genes containing multiple U2-dependent introns. 
Chemically, splicing proceeds via two successive transesterification reactions (Fig. 
1.1). The branch point A residue plays a critical role in the enzymatic reaction. The 
first step is a nucleophilic attack. The 2' hydroxyl group of the conserved adenosine 
within the branching site attacks the the 5' splice site at the exon1-intron junction. 
An unusual 2'-5' phosphodiester bond is made between both residues and the 
exon1-intron junction is cleaved. The products are a 2'-5' phosphodiester RNA lariat 
structure and a free 3'-OH (leaving group) at the upstream exon. The second step 
is another nucleophilic attack. The 3'-OH end of the released exon1 then attacks 
the scissile phosphodiester bond of the conserved guanosine of the 3' splice site at 
the intron-exon2 junction. This reaction liberates the 3'-OH of the intron resulting in 
a free lariat and spliced exons. The two exon sequences are joined together, while 
the intron sequence is released as a lariat structure (Moore and Sharp, 1993). The 
spliceosome, which catalyses the two transesterification steps, is described in more 
detail in the next chapter. 
 
1.2 Spliceosome assembly 
 
 
The spliceosome is a macromolecular machinery that catalyses the removal of 
introns from eukaryotic pre-mRNA (Staley and Guthrie, 1998). It is formed from five 
small nuclear ribonucleoprotein particles (U snRNPs) together with an additional 
group of spliceosome-associated splicing factors. This complex is highly dynamic 
and changes its structure and composition during splicing. 
Each U snRNP particle consist of a U snRNA (uridine-rich small nuclear RNA) 
complexes with a common set of 7 core proteins (Sm or Sm-like (LSm) proteins)  
1. Introduction 
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Figure 1.1 Two-step chemical mechanism of pre-mRNA splicing. 
Exons are depicted as boxes, intron as a black line. The branch point adenosine (A), the 5’ and 3’ 
splice sites and polypyrimidine tract are indicated. The first and second steps of transesterification 
reaction proceed from top to bottom showing the end products (ligated exons and released lariat 
intron) at the bottom panel. 
 
 
and a set of specific proteins unique for each snRNP. U1, U2, U4, U5 and U6 are 
the major spliceosomal snRNPs. In addition, the human spliceosome contains 
numerous non-snRNP proteins. Initial mass spectrometric analysis of mixed 
population of affinity-purified spliceosomal complexes indicated that between 150 
(Zhou et al., 2002) and 300 distinct proteins (Rappsilber et al., 2002) co-purify with 
the spliceosome. 
The spliceosome assembles de novo on each intron through a sequential and 
highly coordinated pathway (Fig. 1.2). Initiation of pre-spliceosome assembly or E 
complex formation begins with ATP-independent binding of the U1 snRNP through 
base-pairing interactions of the 5’ end of the U1 snRNA with the 5’ splice site of the 
intron. This interaction in higher eukaryotes is stabilised by members of the serine-
arginine-rich (SR) protein family and proteins of the U1 snRNP (Valcarcel and 
Green, 1996). In addition to the U1-5’ splice site interaction, the earliest assembly 
phase of the spliceosome also involves the binding of the SF1/BBP protein and the 
U2 auxiliary factor (U2AF) to the BPS and the polypyrimidine tract just downstream 
of the BPS, respectively (Black, 2003). The U2 snRNP is then recruited to the 
branch point sequence via base-pairing between the pre-mRNA and the U2 snRNA 
1. Introduction 
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in an ATP-dependent manner, generating the A complex. The B complex is formed 
by the recruitment of the U4/U6•U5 tri-snRNP to the pre-spliceosome. The 
spliceosome becomes catalytically active upon rearrangement and destabilisation 
of U1 and U4 snRNPs, which leads to the recognition of part of the 5’ splice site by 
U6 snRNA (Staley and Guthrie, 1998; Nilsen, 2003). The activated spliceosome 
then carries out the first catalytic step of splicing, generating the C complex. Prior to 
the second catalytic step, additional rearrangements occur in the spliceosomal RNP 
network (Konarska et al., 2006). After the second catalytic step, the spliceosome 
dissociates, releasing the mRNA. It also releases the U2, U5, and U6 snRNPs to be 
recycled for new rounds of splicing. 
There are two distinct types of spliceosomes, the major (or U2-type) spliceosome 
and the minor (or U12-type) spliceosome. The spliceosome discussed above is the 
major spliceosome. 
 
 
 
Figure 1.2 Spliceosome assembly cycle. 
Pre-mRNA with two exons and one intron (black boxes and black line, respectively) is shown on the 
top. The branch point adenosine (A*), the 5’ (GU) and 3’ (AG) splice sites are indicated. 
Spliceosomal U1, U2, U4, U5 and U6 snRNPs (coloured cycles) associate with pre-mRNA in a 
stepwise manner. Three main steps: spliceosome assembly, splicing catalysis and snRNP recycling 
are marked by yellow boxes. Secondary structures of U6 snRNP, U4/U6 di-snRNP and base-pairing 
of U2/U6 in the active spliceosome are indicated in the yellow boxes. The two transesterification 
reactions taking place in catalytic center of the spliceosome are indicated by red arrows. After 
splicing and spliceosome dissociation snRNPs take part in a new round of the splicing cycle. 
(provided by Dr. J.Medenbach) 
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The two types of the spliceosome share the U5 snRNP, but each has four other 
specific snRNPs: U1, U2 and U4/U6 in the U2-type spliceosome, and their low-
abundant functional analogues, namely U11, U12 and U4atac/U6atac in the U12-
type spliceosome (Tarn and Steitz, 1997; Burge et al., 1998). Each snRNA differs 
from its analogues in the primary sequence but they share a remarkable similarity in 
the secondary structure (Tarn and Steitz, 1997). Moreover, the two spliceosomes 
contain a large common set of protein components, and the intricate network of the 
RNA–RNA interactions is strikingly similar in each spliceosome (Will and Luhrmann, 
2005; Patel et al., 2003). Nevertheless, the individual spliceosomes can only 
catalyze the removal of their cognate introns. 
 
1.3 Alternative splicing 
 
 
Sequencing of the human genome a few years ago revealed a great surprise. 
Instead of supporting the expected number of 100,000-140,000 genes, nowadays 
only around 23,000 genes are assumed (MCkernan et al., 2009). This number is 
not much bigger compared to the primitive nematode C.elegans (19,000 genes). 
However, the diversity of the human proteins is clearly more complex compared to 
invertebrates. Alternative splicing is a crucial mechanism, allowing individual genes 
to express multiple mRNAs that encode proteins with diverse and even antagonistic 
function (Fig. 1.3). Notable example is the Drosophila Dscam gene, which codes for 
a cell surface protein involved in neuronal connectivity. The combinatorial 
alternative splicing of the exons can potentially generate up to 38,000 different 
protein isoforms, more then twice the number of genes in entire Drosophila genome 
(Graveley et al., 2001). Bioinformatics analysis based on aligning ESTs to the 
genomic sequence shows that 59% of 245 genes present on chromosome 22 are 
alternatively spliced (Modrek et al., 2001). The high frequency of alternative splicing 
in humans is also supported by EST based database analysis, indicating that 35–
60% of all human gene products are alternatively spliced (Mironov et al., 1999; Kan 
et al., 2001; Modrek et al., 2001). DNA microarray experiments indicate that 95% of 
all human genes are alternatively spliced (Wang et al., 2008). 
Alternative splicing in protein-coding regions generates segments of mRNA 
variability that can insert or remove amino acids, shift the reading frame, or 
introduce the termination codon (Fig. 1.3). Thus, changes in the protein sequence 
can influence almost all aspects of protein function, such as binding properties, 
enzymatic activity, intracellular localisation, phosphorylation and glycosylation 
patterns. Alternative splicing in 5’ and 3’ untranslated regions (UTRs) affects gene 
1. Introduction 
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expression by removing or inserting regulator elements controlling translation, 
mRNA stability, or localisation. 
Some protein isoforms might be generated by alternative splicing in a tissue- or 
developmental stage-specific manner. In this case, alternative splicing undergoes 
cell-specific regulation in which splicing pathway are modulated according to cell 
type, developmental stage, gender or in response to external stimuli. 
There are five major patterns into which alternative splicing events can be 
classified: cassette exons, mutually exclusive exons, retained introns, the use of 
alternative 5’ splice sites and alternative 3’ splice sites (Fig. 1.4). Recently, it has 
been found that the usage of alternative promoters and poly (A) sites further 
contributes to isoform diversity. 
 
 
 
 
AAAAA 
Protein Coding Sequence 5’ UTR 3’ UTR 
AAAAA AAAAA 
Change in protein  
  expression level 
Altered protein structure and function  
    Change in protein isoform ratios 
mRNA instability  
Change in protein 
expression level 
 
 
 
Figure 1.3 The impact of alternative RNA splicing. 
Alternative splicing can occur in any region of nascent mRNA. The 5’UTR sequence contains 
regulatory regions that control protein expression. Insertion or deletion of these regions will have a 
consequence on protein expression. The 3’UTR region contains mRNA stability domains. Insertion 
or deletion of these domains will have a consequence on mRNA stability and therefore protein 
expression. Alternative splicing within the protein coding sequence results in altered protein 
structure and function. Exons and introns are represented by coloured cylinders and black lines, 
respectively. Alternative splicing patterns are indicated by brown lines. 
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Figure 1.4 Patterns of alternative splicing.  
The exons are indicated as boxes. Introns are indicated as thick black lines. Alternative splicing 
patterns are indicated as thin lines. P1/P2: alternative promoters; AAAA…: poly A sites. 
 
1.4 Mechanism of splicing regulation 
 
 
1.4.1 Splicing enhancers and silencers 
 
 
The most remarkable features of the mammalian pre-mRNA splicing machinery are 
its ability to select precisely correct pairs of splice sites, reliably distinguish 
authentic exons from pseudo-exons, and modulate the selection of alternative 
splice sites. The weakly conserved consensus sequences marking exon/intron 
borders are loosely defined, very short and degenerated, and provide less than 
50% of the necessary information for accurate removal of introns in human (Lim 
and Burge, 2001). The spliceosome machinery must rely on additional auxiliary 
sequence features. Additional RNA sequence elements (cis-acting elements) 
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provide the necessary information for either activation or repression of constitutive 
and alternative splicing. Motifs that promote splicing are called enhancers, while 
those that inhibit splicing are named silencers. Depending on the position and 
function of the cis-regulatory elements, they are divided into four groups: exonic 
splicing enhancer (ESE), exonic splicing silencer (ESS), intronic splicing enhancer 
(ISE) and intronic splicing silencer (ISS). These elements have a loosely defined, 
very short (6-8nt), degenerate and partially overlapping consensus sequences. 
Several types of enhancer/silencer elements have been identified by functional 
SELEX (Systematic Evolution of Ligands by EXponential enrichment) experiments 
in vivo and in vitro (reviewed in Zheng, 2004): the purine-rich and non-purine-rich 
sequences, and adenosine/cytosine-rich elements (ACEs) (Coulter et al., 1997). 
Recent global studies have discovered that the relative enrichment in exonic 
splicing enhancers (ESEs) and exonic splicing silencers (ESSs) helps 
distinguishing between authentic and pseudoexons (Zhang and Chasin 2004; 
Zhang et al., 2005; Wang et al., 2004). 
The exonic splicing enhancers (ESEs) are the most studied. They are common in 
both alternative and constitutive exons. ESEs are specific short nucleotide 
sequences that are targeted essentially by SR proteins which then promote exon 
definition (Blenowe, 2000). Conversely, the exonic splicing silencers (ESSs) help 
the spliceosome to ignore pseudoexons and decoy splice sites. They act as binding 
sites for proteins promoting exon exclusion (mainly hnRNP proteins) (Zhu et al., 
2001). Besides their role in constitutive splicing, ESEs and ESSs play an important 
role in the regulation of alternative splicing (Black, 2003). The mutation in ESEs can 
result in skipping the mutant exon, with dramatic effect on the structure of gene 
product (Cartegni et al., 2002). 
Intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs) are intronic 
cis-elements that play similar roles as ESEs and ESSs. Recently, intronic CA-rich 
and CA-repeat elements were describe as cis-regulatory elements that play an 
important role in regulation of alternative splicing (Hui et al., 2005; Hung et al., 
2008; Heiner et al., 2010). 
Splicing enhancers are located close to the splice sites that they activate. However, 
the action of splicing enhancers is position dependent. Changing the location of 
splicing enhancers alters their dependence on particular trans-acting factors (Tian 
and Maniatis, 1994), and determines whether they activate 5’ or 3’ splice sites 
(Heinrichs et al., 1998). It can even transform them into negative regulatory 
elements (Kanopka et al., 1996). 
Proteins binding to enhancer or silencer sequences and modulating the alternative 
splice site selection can be subdivided into two major groups: members of the SR 
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family of proteins and hnRNPs. These groups are described in more detail in the 
next chapters. 
 
 
1.4.2 SR and SR-related proteins 
 
 
SR proteins are a family of phylogenetically conserved, structurally related, 
essential pre-mRNA splicing factors. Members of the SR family have a modular 
structure consisting of one or two copies of an N-terminal RNA recognition motifs 
[RRMs or so-called RNA-binding domain (RBD)] followed by a variable-length C-
terminal domain enriched in serine and arginine dipeptides, known as the RS 
domain (Fig. 1.5A). The RRMs determine RNA-binding specificity, whereas the RS 
domain functions as a protein–protein interaction module by recruiting components 
of the core splicing apparatus to promote splice site pairing (Wu and Maniatis, 
1993). More recently, it has also been demonstrated that the RS domain can 
directly contact both the pre-mRNA branch point and the 5’ splice site (Shen et al., 
2004). The extensive serine phosphorylation of the RS domain plays an important 
role in regulating the activities and localisation of SR proteins (Sanford and 
Longman, 2003). 
SR-related proteins are a group of additional splicing factors containing RS 
domains and structurally and functionally related to SR family proteins (Fig. 1.5B) 
(Fu, 1995, Blencowe et al., 1999). Some SR-related proteins, such as U2AF65, 
U2AF35, U1-70K are directly involved in constitutive and alternative splicing. 
Interactions between SR and SR-related proteins allow mediating communication 
between the 5′ and 3′ splice sites during the early stages of spliceosome assembly 
(Blencowe, 2000). 
The presence of different SR proteins in mammalian cells suggests that they 
regulate RNA splicing specifically. The RNA-binding specificity of each SR protein 
was identified by functional SELEX approach. This approach led to identification of 
both purine- and non-purine-rich SR protein-specific ESEs (Schaal and Maniatis, 
1999). Those studies also established that SR proteins are sequence-specific RNA-
binding proteins with distinct RNA-binding specificity. 
The activity of SR proteins in constitutive and alternative splicing regulation relies 
principally on their interactions with RNA regulatory sequences. SR-protein-binding 
sites within exons (ESEs) exert a positive effect on splice site selection, whereas 
intronic binding sites for SR proteins repress splice site selection (Kanopka et al., 
1996). 
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For example, SR proteins, bound to ESEs, recruit and stabilise the binding of U1 
snRNP and U2AF to the 5’ and 3’ splice sites, respectively, in a process known as 
exon definition (Fig. 1.6A) (Boukis et al., 2004). SR proteins have been shown to 
facilitate the recruitment of the U4/U6•U5 tri-snRNP to the pre-spliceosome (Fig. 
1.6B) (Roscigno and Carcia-Blanco, 1995). The binding of SR proteins to intronic 
cis-element prevents binding of U2AF65 and U2AF35 to the 3’ splice site (Fig. 
1.6C). 
 
 
 
Figure 1.5 Schematic diagram of human SR and SR-related proteins. 
Domain structures of known members of the human SR protein family (A) and SR-related proteins 
(B) are depicted. RRM (RNA recognition motif) and RRMH (RRM homology) are shown as light red 
boxes, Zinc knuckle (Z) as a green box, RS domain as a dark red box, DEXD/H Box: motif 
characteristic for RNA helicases (adapted from Graveley et al., 2000). 
 
 
SR proteins are key players in the regulation of alternative splicing. Many 
alternative exons carry weak splicing signals; for instance, many alternative 3’ 
splice site contain poor polypyrimidine tracts, which are recognised inefficiently by 
U2AF, resulting in exon skipping. However, SR proteins, bound to ESEs, can 
compensate for a weak polypyrimidine tract by recruiting U2AF (Wang and Smith, 
2005). Alternatively, ESE-associated SR proteins may promote alternative exon 
inclusion by antagonising the negative activity of hnRNPs (heterogeneous nuclear 
ribonucleoproteins), such as hnRNP A1, bound to exonic splicing silencer elements 
(Fig. 1.6D) (Blencowe, 2000). 
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Figure 1.6 Splicing functions of SR proteins. 
(A) SR proteins (green), bound to an ESE, may function in constitutive splicing by interacting with 
the splicing factors U2AF bound at the upstream 3' splice site and U1 snRNP bound to the 
downstream 5' splice site. Py represents the polypyrimidine tract, the binding site for U2AF. (B) Two 
exon-independent functions of SR proteins. SR proteins facilitate splice-site pairing by 
simultaneously interacting with U1 snRNP and U2AF across the intron. SR proteins also assist in 
recruiting the U4/U6U5 tri-snRNP. (C) Splicing repression is mediated when SR proteins associate 
with intronic sequences close to the splice sites (adapted from Shepard and Hertel, 2009). (D) SR 
protein, bound to an ESE, antagonises the negative effect on splicing of an inhibitory protein bound 
to a juxtaposed ESS. 
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1.4.3 HnRNP proteins 
 
 
The nuclear protein-coding transcripts that are produced by RNA polymerase II are 
termed pre-mRNAs or hnRNAs (heterogeneous nuclear RNA, historical term that 
described their size heterogeneity and cellular location). Nascent pre-mRNAs are 
associated with specific proteins with which they form complexes termed 
heterogeneous nuclear ribonucleoprotein (hnRNP) particles. The collective term for 
the proteins that bind hnRNAs is hnRNP proteins (Dreyfuss et al., 1993, Krecic and 
Swanson, 1999). HnRNP proteins are a diverse family of abundant nuclear RNA-
binding proteins which are involved in many RNA-related biological processes such 
as transcriptional regulation, telomere-length maintenance, pre-mRNA processing, 
mRNA stability and export to cytoplasm, and translation (Kim et al., 2000). 
Approximately, 20 major hnRNPs with molecular mass range from 34 kDa to 120 
kDa have been identified, and are designated from hnRNP A1 to U (Dreyfuss et al., 
2003). All hnRNP proteins share a common structure containing various types of 
RNA-binding domains (RRM, KH, RGG) and auxiliary domains (rich in glycine and 
other amino acids), which might mediate protein-protein interaction or act in a 
protein localisation. Many of the arginine residues within the RGG box are potential 
methylation sites, which could play a role in regulation of the RNA-binding activity. 
Arginine methylation and serine/threonine phosphorylation are common 
modifications for several hnRNP proteins (Liu and Dreyfuss, 1995; Schutt et al., 
2001). 
Initially it was thought that hnRNP proteins bind non-specifically to hnRNA. Later 
the binding specificities for most of hnRNP proteins were identified by SELEX and 
CLIP assay. For example, the sequence GGGA is recognised by all hnRNP H 
family proteins (Caputi and Zahler, 2001), hnRNP L protein recognises CACA 
motifs (Hui et al., 2005), and hnRNP I (PTB) protein specifically binds to UCUU 
motif (Perez et al., 1997). 
HnRNP proteins, similar as SR proteins, participate in the regulation of alternative 
splicing. In contrast to SR proteins, most hnRNPs tend to interact with splicing 
silencer sequences and function as splicing repressors (Matlin et al., 2005). Some 
hnRNP proteins prevent binding of other splicing factors to the splicing control 
elements within pre-mRNA by forming complexes with RNA and/or other proteins 
(Fig. 1.7A) (Zhu et al., 2001). HnRNP proteins also mediate long-range interactions 
between distant RNA regions flanking alternative exons, thus looping out the 
intervening region of the pre-mRNA and preventing splicing of the excluded RNA 
region (Fig. 1.7B) (Blanchette and Chabot, 1999; Martinez-Contreras et al., 2006). 
In several cases, hnRNP proteins have been found to antagonise, both in vitro and 
1. Introduction 
 19 
in vivo, the activity of SR proteins (Mayeda et al., 1993; Zhu et al., 2001). Several 
proteins, such as hnRNP L, hnRNP LL, hnRNP F and hnRNP H have been shown 
to act either as a repressor or an activator depending on the location of their binding 
sites (Hui et al., 2005; Mauger et al., 2008). 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Figure 1.7 Splicing functions of hnRNP proteins.  
(A) Splicing repressors such as hnRNP proteins can inhibit splicing by binding to intronic splicing 
silencers (ISSs), where they interfere with the binding of U2AF to the 3' splice site. (B) Alternatively, 
hnRNP proteins can bind to ISSs in the introns flanking an exon, where they engage in protein-
protein interactions and loop out the intervening exon (adapted from Graveley, 2009). 
 
 
1.5 RNA-binding motifs 
 
 
RNA-binding proteins play key roles in post-transcriptional control of pre-mRNA, 
which can occur at many different steps in RNA metabolism, including splicing, 
polyadenylation, mRNA stability, mRNA localisation and translation. The diversity of 
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function of RNA-binding proteins would suggest a correspondingly large diversity in 
the structures that are responsible for RNA recognition. However, most RNA-
binding proteins are built from few RNA-binding domains. Some well-characterised 
RNA-binding domains include the following: RNA-binding domain (RBD, also known 
as RNA recognition motif, RRM); K-homology (KH) domain; RGG (Arg-Gly-Gly) 
box; Zinc finger (ZnF, mostly C-x8-C-x5-C-x3-H type); cold-shock domain (Y-box 
proteins); DEAD/DEAH box; Pumilio/FBF (PUF) domain; double-stranded RNA-
binding domain (dsRBD); Piwi/Argonaute/Zwille (PAZ) domain; Sm domain, etc.  
Many RBPs have one or more copies of the same RBD while others have two or 
more distinct domains. Individual RBDs are separated by linker sequences of highly 
variable length. These linkers provide a critical determinant of binding affinity. In 
many cases, individual RBDs within the same protein have different binding 
specificities, which suggest they may allow a single protein to bridge multiple RNAs 
(trans) or multiple RBDs may interact with non-specific RNA lattice to increase 
binding affinity (cis) (Shamoo et al., 1995). 
 
 
1.5.1 RNA recognition motif 
 
 
The RNA recognition motif, also known as RNA-binding domain or 
ribonucleoprotein domain (RNP) is one of the most abundant protein domains in 
eukaryotes. In human, 497 proteins containing at least one RRM have been 
identified (Venter, 2001). In eukaryotic proteins, RRMs are often present as multiple 
copies within a protein (44%, two to six RRMs) and/or together with other domains 
(21%) (Maris et al., 2005). RRM-domain-containing proteins are involved in many 
cellular functions, particularly messenger RNA and ribosomal RNA processing, 
splicing and translation regulation, RNA export and RNA stability (Dreyfuss et al., 
2002). 
Typically, an RRM is approximately 90 amino acids long with a typical βαββαβ 
topology that forms a four-stranded β-sheet packed against two α–helices 
(exemplified here by RRM3 and RRM4 of PTB; Fig. 1.8). The main protein surface 
of the RRM involved in the interaction with the RNA is the four-stranded β-sheet, 
which usually contacts a variable number of nucleotides, ranging from a minimum 
of two in the case of CBP20 RRM (Calero et al., 2002; Mazza et al., 2002) to a 
maximum of eight for U2B’’ RRM1 (Price et al., 1998). 
The most conserved RRM signature sequence is an eight-residue motif called 
RNP1 (in β3-sheet), which has the consensus [RK]-G-[FY]-[GA]-[FY]-[ILV]-X-[FY]. A 
second six-residue region of homology, called RNP2 (in β1-sheet), is typically 
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located 30 residues N-terminal to RNP1, and has the consensus [ILV]-[FY]-[ILV]-X-
N-L. Additional conserved amino acids define an 80-residue domain that 
encompasses the RNA-binding function (Scherly et al., 1989). 
Recently structural studies emphasise that not only the β-sheet surface but also the 
loops connecting β-strands and α–helices can be crucial for nucleic acid 
recognition. For example, one loop for ASF/SF2 RRM2 (Tintaru et al., 2007), two 
loops for Fox-1 (Auwert et al., 2006) and three loops for hnRNP F (Dominguez and 
Allain, 2006) are crucial for nucleic acid interactions. 
Some individual RRMs can bind to RNA with great specificity, but multiple domains 
are often needed to define specificity because number of nucleotides that are 
recognised by an individual RRM is generally too small to define a unique binding 
sequence (Auwert et al., 2006). 
 
 
 
Figure 1.8 Ribbon diagrams for RRMs 3 and 4 of PTB. 
The fold is composed of one four-stranded antiparallel beta-sheet specially arranged in the order β4-
β1-β3-β2 from left to right (in green) and two helices α1 and α2 (in purple)  packed against the beta-
sheet. PTB RRM3 contains an additional strand (β5) (in blue) on the side of the RNA-binding 
surface. (Conte et al., 2000). 
 
1.6 HnRNP L and LL 
 
 
The heterogeneous nuclear ribonucleoprotein (hnRNP) L is a very abundant 
nuclear RNA-binding protein of 64 kDa (Pinol-Roma et al., 1989). Several diverse 
functions for hnRNP L have been reported, including its binding in a sequence-
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specific manner to cis-acting RNA sequence elements that enables intron-
independent gene expression and facilitate nuclear export of intronless genes 
(Guang et al., 2005; Liu and Mertz, 1995). It has been shown that hnRNP L binds to 
the pre-mRNA processing enhancer of the herpes simplex virus thymidine kinase 
intronless mRNA and enhances its cytoplasmic export. The binding of hnRNP L to 
the HCV IRES correlates with the translation efficiency of HCV mRNAs (Hahm et 
al., 1998b). More recently, hnRNP L has been shown to regulate the stability of 
human vascular endothelial growth factor (VEGF) mRNA in response to hypoxia 
(Shin and Claffey, 1999; Ray et al., 2008). Another example of function hnRNP L in 
mRNA stability is the human endothelial nitric synthase (eNOS) gene (Hui et al., 
2003a). In addition to its role as a sequence-specific RNA protection factor, hnRNP 
L can act as a splicing regulator. It has been shown that differential binding of 
hnRNP L to intronic CA-rich sequences of a different length is the mechanism 
responsible for regulation of mRNA splicing in the human eNOS gene. The largest 
intron 13 in eNOS carries a polymorphic CA-rich region (14-44 repeats), and 
hnRNP L binds preferentially to the longer CA-rich sequence. Moreover, the length 
of the polymorphic CA-rich region in the eNOS gene has been correlated with an 
independent risk factor for coronary artery disease (Stangl et al., 2000). 
With an in vitro SELEX approach, the binding specificity of hnRNP L has been 
determined (Fig. 1.9). The sequences obtained showed an enrichment of CA 
dinucleotides with ACAC and CACA representing the minimal high-score binding 
motifs for hnRNP L. In addition, hnRNP L recognises with high affinity certain CA-
rich clusters (Hui et al., 2005).  
Recently, hnRNP L protein was characterised as a global regulator of alternative 
splicing. Many other target genes were identified besides eNOS. It was reported 
that skipping of the CD45 variable exons 4 and 5 is regulated by binding of hnRNP 
 
 
 
Figure 1.9 Sequence motif recognised by hnRNP L. 
The 10-nucleotide consensus sequence defined by SELEX approach. The frequency of each of the 
four nucleotides at any position in the consensus is represented by the letter height. Boxes mark the 
two highly conserved core tetranucleotides (Hui et al., 2005). 
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L to an activation-responsive sequences (ARSs) that is located within each exon 
(Rothrock et al., 2005; Tong et al., 2005; Motta-Mena et al., 2010). 11 more target 
genes of hnRNP L were identified on a global level by combination of splice-
sensitive microarray analysis and an RNAi-knockdown approach (Hung et al., 
2008). Among them SLC2A2 and TJP1, whose mechanistic basis of hnRNP L-
regulated alternative splicing were investigated in detail (Heiner et al., 2010). 
Recently, hnRNP L-like (hnRNP LL), a closely related paralog of hnRNP L, was 
also characterised as a global regulator of alternative splicing in activated T cells 
(Oberdoerffer et al., 2008; Wu et al., 2008). It was reported that hnRNP LL plays an 
important role in regulation of alternative splicing of CD45 exon 4 (Topp et al., 
2008). HnRNP LL expression was induced upon T-cell stimulation and promoted 
CD45 exon 4 skipping during T-cell activation. 
HnRNP L and its paralog hnRNP LL share 58% of overall amino acid identity and 
similar size (558 vs. 542 amino acids) (Fig. 1.10). Both proteins contain four 
classical RNA recognition motifs (RRMs). The alignment of each individual RRM of 
hnRNP L and hnRNP LL shows that all RRMs are highly conserved, with RRM2 
being most conserved. The N-terminal glycine-rich regions of hnRNP L is less 
pronounced in the LL paralog, and the proline-rich regions between RRMs 2 and 3 
of hnRNP L are absent in LL. In HeLa cells hnRNP LL is about ten times less 
abundant than hnRNP L (Hung et al., 2008). This observation and its participation 
in T-cell activation-induced alternative splicing suggest a tissue-specific role for 
hnRNP LL. 
Previously, it has been shown that hnRNP L and hnRNP LL intarects in vivo with 
each other in JSL1 cells (Oberdoerffer at al., 2008) 
 
 
 
 
Figure 1.10 Domain structure of the hnRNP L and hnRNP LL proteins.  
The domain structure of hnRNP L (P14866; 589 amino acids) and hnRNP LL (Q53T80; 542 amino 
acids) are schematically represented. Four classical RRM motifs are shown as green boxes, the 
glycine- and proline-rich regions are shown as orange and blue boxes, respectively.  
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1.7 Alternative splicing and disease 
 
 
As alternative splicing affects numerous genes, it is not surprising that changes in 
alternative splicing are frequently associated with human diseases and cancer. It 
has been estimated that 15% of all point mutations causing human genetic 
diseases (Krawczak et al., 1992). This is likely to be an underestimate because the 
analysis was limited to mutations in the classical splice-site sequences. It is known 
that widespread aberrant splicing is also caused by mutations that disrupt exonic 
splicing elements (ESEs and ESSs) (Faustino and Cooper, 2003). Thereby, the 
mutations can be subdivided into two types. Type I mutations affect invariant 
positions of splice sites resulting in disruption of canonical splice sites. These 
mutations are responsible for 9-10% of the genetic diseases that are caused by 
point mutations (Wang and Cooper, 2007). Type II mutations occur in variant 
positions of splice sites, in enhancer or silencer regions. For some genes, up to 
50% of point mutations within exon affected splicing; and it has been hypothesised 
that more than half of known disease-causing mutations disrupt splicing (Lopez-
Bigas et al., 2005). 
Familial dysautonomia (FD) is an example for a disease caused by a mutation in 
the 5’ splice site (Maayan et al., 1987; Carmel et al., 2004). FD is a recessive 
disease that caused by loss of function of the i-kappa-B kinase complex associated 
proteins (IKBKAP). Affected children show abnormal development of the nervous 
system that is associated with demyelination in various regions. U1 snRNA 
interacts with nine nucleotides at 5’ splice site (three nucleotides of the exon and 
first six nucleotides of the downstream intron). The majority of 5’ splice sites show 
complementarity to seven base pairs of U1 snRNA. This means there are usually 
three mismatches between U1 snRNA and the 5’ splice site, which are not 
randomly distributed. Usually either the exonic portion of the 5’ splice site is 
weakened due to some mismatches, or the intronic portion. In both cases the 
weaker portion is compensated by strong intronic or exonic portion, respectively 
(Siliciano and Guthrie, 1988). In exon 20 of the IKBKAP gene, the exonic part of the 
splice site is weak, due to an A at position -1. The mutation T→C in position 6 of 
intron 20 weakens the intronic part of the 5’ splice site. This interrupts base paring 
with U1 snRNP, which causes exon skipping. 
Spinal muscular atrophy (SMA) is an example of the detrimental effect of a single 
nucleotide substitution in exonic splicing signal in the survival of motor neuron 2 
(SMN2) gene. SMA is a recessive autosomal disorder characterised by 
degeneration of spinal cord motor neurons leading to muscle atrophy (Cartegni et 
1. Introduction 
 25 
al., 2006; Frugier et al., 2002). In humans, there are two SMN genes, SMN1 and 
SMN2, both of which encode the same open reading frame. SMN protein plays a 
critical role in snRNP biogenesis. The vast majority of SMA patients have deletions 
of the SMN1 gene, but retain SMN2. But single nucleotide substitution C→T at 
position 6 in exon 7 of SMN2 gene significantly alters the splicing pattern of SMN2 
pre-mRNA, causing frequent skipping of exon 7, probably due to the disruption of 
an ESE element within exon. Thus, SMN2 gene, producing a truncated and non-
functional protein, is not able to completely compensate for the loss of SMN1 
protein. 
1.8 Specific aims 
 
As described above, hnRNP L and its paralog hnRNP LL are the RNA-binding 
proteins playing the important roles in alternative splicing regulation. Both proteins 
as typical RNA-binding proteins contain four classical RRMs. The presence of 
multiple RNA-binding domains immediately raises the question about the 
contribution of individual domains in RNA binding and alternative splicing 
regulation. 
 
In the first part of my thesis I aimed to study RNA-binding properties of hnRNP L 
and hnRNP LL proteins and the role of the individual domains in binding to two 
different substrates: CA-repeat and CA-rich RNAs. Moreover, I intended to test the 
structural feature of hnRNP L, namely inter-domain interaction between RRM3 and 
RRM4, for its role in RNA binding. 
  
In the second part of my thesis I investigated how hnRNP L binds to unusually long 
CA-rich cluster within its own pre-mRNA. The results obtained provide further 
insights how the cell can autoregulate its hnRNP L level. 
 
In the third part of my thesis I aimed to determine the important features within CA-
rich RNA (number of high-score binding motifs and the length of the spacers 
between them) required for high-affinity binding of hnRNP L. 
 
In the fourth part of my thesis I aimed to study the contributions of individual RRMs 
as well as the glycine-rich region in the splicing repression function of hnRNP L. 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals and reagents 
 
Acetic acid Roth 
Aceton Roth 
Acrylamide  Bio-Rad 
Acrylamide/bisacrylamide 30, 30%, 37,5:1  Roth 
Acrylamide/bisacrylamide 40, 40%, 19:1  Roth 
Agarose ultra pure  Roth  
Ammonium persulfate (APS)  Bio-Rad 
Ampicilin  Roth  
Bacto-agar Roth 
Bacto-trypton Roth 
Bacto-yeast extract Roth 
Bisacrylamide  Bio-Rad 
Boric acid  Roth  
Bovine serum albumin, RNase free  Roche 
Bromophenol blue  Merck  
5-bromo-4-chloro-3-indolyl-β-D- 
galactopyranoside (X-Gal)  
Roche 
Calcium chloride  Merck 
Chloroform Roth  
Coomassie brilliant blue R250  Merck 
Creatine phosphate  Roche 
Dimethyl pyrocarbonate (DMPC)  Sigma 
Di-sodium hydrogenphosphate dehydrate 
(Na2HPO4·2H20)  
Merck 
Dithioreitol (DTT)  Roche 
Ethanol absolute  Roth 
Ethidium bromide  Roth 
Ethylendiaminetetraacetic acid (EDTA)  Roth 
Ethylen glycol Roth 
Formamide Roth 
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Glucose  Sigma 
Glycerol  Roth 
Glycin  Roth  
Glycogen  PeqLab 
Heparin  Sigma 
N-2-hydroxyethylpiperazine (HEPES)  Sigma 
Imidazole  Roth  
Isoamyl alcohol  Roth 
Isopropanol  Roth 
Isopropyl-1-thio-β-D-galactoside (IPTG)  Roche 
Kanamycin  Sigma  
Lysozyme  Sigma  
Magnesium chloride  Merck 
Magnesium sulfate  Sigma  
2- mercaptoethanol Roth 
Methanol  Roth 
Nonidet P-40 /Igepal CA-630 Sigma 
Phenylmethylsulfonyl fluoride (PMSF)  Roth 
Polyoxyethyleneorbiten monolaurate (Tween20)  Sigma 
Polyvinylalcohol  Merck 
Potassium chloride (KCl)  Roth 
Roti-phenol  Roth 
Roti-phenol/chloroform  Roth 
Sodium acetic acid (NaAc)  Merck 
Sodium chloride (NaCl)  Roth 
Sodium citrate  Roth 
Sodium dihydrogen phosphate monohydrate 
(NaH2PO4·2H20)  
Merck 
Sodium dodecyl sulfate (SDS)  Roth 
Tetracycline Sigma 
N,N,N´,N´-tetramethylenediamine (TEMED)  Bio-Rad 
Tris-hydroxymethylaminomethane (Tris)  Roth 
Triton X-100  Merck 
tRNA from yeast  Roche 
urea  Roth 
Xylene cyanole FF  Sigma  
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2.1.2 Nucleotides  
 
deoxynucleoside triphosphate set (dNTP, 100 mM) Roche 
m7GpppG cap analog Biozym 
ribonucleoside triphosphate set (NTP, 100 mM) Roche 
[α-32P]ATP (3,000 Ci/mmol, 5 µCi/µl) Hartmann Analytic 
[α-32P]CTP (800 Ci/mmol, 10 µCi/µl) Hartmann Analytic 
 
 
2.1.3 Enzymes and enzyme inhibitors 
 
AcTEV Protease (10 U/ µl) Invitrogen 
Protease inhibitor cocktail tablets Roth 
Poteinase K (PK, 10 µg/µl) Roche 
Pwo DNA polymerase Roth 
Restriction endonucleases New England Biolabs 
RNase A (100 mg/ml) Qiagen 
RNase inhibitor  (RNaseOUT, 40 U/µl) Invitrogen 
RQ1 RNase free DNase (1 U/µl) Promega 
Shrimp alkaline phosphatase (SAP, 1 U/µl) Roche 
Taq DNA polymerase (5 U/µl) Own purification 
T4 DNA ligase, (400 U/µl) New England Biolabs 
T7 RNA polymerase (20 U/µl) Fermentas 
qScript reverse transcriptase Quanta Biosciences 
 
 
2.1.4 Reaction buffers  
 
10x Pwo Polymerase buffer Roth 
10× restriction enzyme buffer 1, 2, 3, and 4 New England Biolabs 
10× RQ1 DNase buffer Promega 
10× SAP buffer Roche 
10× Taq polymerase buffer Promega 
 5× T4 DNA ligase buffer New England Biolabs 
 5× transcription optimised buffer Fermentas 
 5× qScript RT buffer Invitrogen 
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2.1.5 Molecular weight markers 
 
GeneRuler DNA ladder mix Fermentas 
Molecular weights 14.000-500.000 marker Sigma 
peqGold protein marker IV PeqLab 
 
 
2.1.6 Kits 
 
BAC-to-BAC baculovirus expression system Invitrogen 
GC-rich PCR system Roth 
MEGAshortscript kit Ambion 
TOPO TA cloning kit Invitrogen 
QIAGEN RNA/DNA mini kit QIAGEN 
QIAGEN plasmid maxi kit QIAGEN 
QIAprep spin miniprep kit QIAGEN 
QIAquick gel extraction kit QIAGEN 
Silver stain kit  Bio-Rad 
 
 
2.1.7 Plasmids 
 
pcDNA3 Invitrogen 
pcDNA3-GSTZ1 described in Hui et al., 2005 
pcDNA3-SLC2A2-Wt, -sub  described in Hui et al., 2005 
pComp-CA32 describe in Hui et al., 2003 
pComp-control describe in Hui et al., 2003 
pFAST-BAC Htb-hnRNP L  described in Hui et al., 2005 
pGEM3Zf(-) Promega 
pGEX-5x-2 Amersham Bioscience 
pRSET-hnRNP L  
 
provided by J. Kim, Pohang University 
of Science and Technology, Korea 
pSP65-MINX  described in Zillman et al., 1988 
pQE30  QIAGEN 
 
 
2.1.8 E.coli strains and cell lines 
 
BL21 Star (DE3) F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) Invitrogen 
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JM109 {genotype: endA1, gyrA96, thi, hsdR17 (rk-, mk+), relA1, 
supE44, ≅(lacproAB), [F´, traD36, proAB, laqlqZ≅M15]} 
Promega 
M15 [pREP4] {genotype: NalS strS rifS thi- lac- ara- gal+ mtl- F- 
recA+ uvr+ lon+ [pREP4 KanR]} 
Qiagen 
Sf21 (Spodopetera frugiperda cell) primary HUVEC cell line Invitrogen 
TOP 10 high-competent cells Invitrogen 
 
 
2.1.9 Antibodies 
 
Anti-FLAG monoclonal antibody Sigma 
Anti-GAPDH monoclonal antibody Sigma 
Anti-His monoclonal antibody Qiagen 
Anti-hnRNP L monoclonal antibody (4D11) Sigma 
Anti-hnRNP L peptide polyclonal antibody (D-17) Santa Cruz Biotechnology 
Anti-hnRNP LL polyclonal antibody home made 
Anti-mouse Immunoglobulin-Peroxidase Sigma 
Anti-rabbit Immunoglobulin-Peroxidase Sigma 
 
 
2.1.10 DNA oligonucleotides 
 
DNA oligonucleotides were ordered from MWG Biotech, Germany 
 
FP cluster A 5’-AATTGGGCCCAACCATACTTCAGCGGCTCT-3’ 
RP cluster A 5’-AATTGGGCCCTTCAAGTTTGCTTGGATTTTGACC-3’ 
FP cluster B 5’-AATTGGGCCCCTGCAGTCACCGGC-3’ 
RP cluster B 5’-AATTGGGCCCGGTGTATGAAGTGGGTAGTGTCC-3’ 
FP cluster ∆ 5’-AATTGGGCCCGGAAGCGGAACACGTAGAAA-3’ 
RP cluster ∆ 5’-AATTGGGCCCAATCATGCGAAACGATCCTC-3’ 
FP-T7-cluster A 5’-AATACGACTCACTATAGGGAACCATACTTCAGCGGCTCT-3’ 
FP-T7-cluster B 5’-AATACGACTCACTATAGGGCTGCAGTCACCGGCTGCCA-3’ 
FP-T7-cluster ∆ 5’-AATACGACTCACTATAGGGGGAAGCGGAACACGTAGAAA-3’ 
5’-KpnI-FP 5’-GGTGGGTACCACAGCCATT-3’ 
FLAG-L-RP 5’-TTAACTCGAGTCTTGTCGTCATCGTCTTTGTAGTCGG 
AGGCGTGCTGAGC-3’ 
hypo-1 (fwd) 5’-CTCGGTAATTGAGAGGAGCG-3’ 
hypo-2 (rev) 5’- CAAGGCAACATGAGATCAACC-3’ 
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hypo-3 (fwd) 5’-TTAAGAATTCCATCCTCCTCCTCTTCCTCC- 3’ 
hypo-4 (rev) 5’-TTAAGTCGACTTATAAATGGGATGATGTAGAAAA 3’ 
LL-KpnI-FP 5’-GGATGGTACCAGCAGCTACAAA-3’ 
LL-FLAG-RP 5’-AATTGCGGCCGCTCACTTGTCGTCATCGTCTTTGTA 
GTCTAAATGGGATGATGTAGAAA-3’ 
2-142 for 5’- TTAAGAATTCACTACTCTACCAGCCAGAAGA-3’    
V225I rev 5’-TTCCTGAAAATGATAATTCTCT-3’ 
V225A rev 5’-TTCCTGAAAATGGCAATTCT-3’ 
SeqI for 5’-AGAGAATTATCATTTTCAGGAAGAATGGAG-3’ 
SeqA for 5’-AGAGAATTGCCATTTTCAGGAAGAATGGAG-3’ 
FLAG-3-471 5’-TTAACTCGAGTCTTGTCGTCATCGTCTTTGTAG 
TCCACGTTGCTGGGGTGCTG-3’ 
L-Full-FP 5’-TTAAGAATTCACATGGTGAAGATGGCGGC-3’ 
L-KpnI-RP 5’-TTAAGGTACCCACCGTGGGGCCCTCCATA-3’ 
L-Full-screen-FP 5’-TGGGGAGAACTACGATGACCC-3’ 
T7-CA1 5’-TAATACGACTCACTATAGGGAGA(CA)20 -3’ 
T7-CA2 5’-(TG)20TCTCCCTATAGTGAGTCGTATTA-3’ 
T7-CA3 5’-TAATACGACTCACTATAGGGAGA(CA)10 -3’ 
T7-CA4 5’-(TG)10TCTCCCTATAGTGAGTCGTATTA-3’ 
T7-UCUU1 5’-TAATACGACTCACTATAGGGAG(TCTT)6 -3’ 
T7-UCUU2 5’-(AAGA)6CTCCCTATAGTGAGTCGTATTA-3’ 
T7-CU3 5’-TAATACGACTCACTATAGGGAGT(CT)10-3’ 
T7-CU4 5’-(AG) 10ACTCCCTATAGTGAGTCGTATTA-3’ 
T7-control-1 5’-TAATACGACTCACTATAGGGAGAcTcTGAAAC 
TGTGCTGAGTT-3’ 
T7-control-2 5’-AACTCAGCACAGTTTCAGAGTCTCCCTATA 
GTGAGTCGTATTA-3’ 
GSTZ1-U1 5’-TAATACGACTCACTATAGGGACACTTGCACCCTTGCACA-3’ 
GSTZ1-U2 5’-TGTGTGAGTGTAAGAGTGT-3’ 
GSTZ1-U3 5’-TAATACGACTCACTATAGGGCTAGTAACGGCCGCCAGT-3’ 
GSTZ1-U4 5’-GATGGATATCTGCAGAATTC-3’ 
SLC2A2 fwd 5’-GGGCTGAGGAAGAGACTG-3’ 
SLC2A2 rev 5’-ACTAATAAGAATGCCCGTGACG-3’ 
MINX E1 fwd 5’-GAATACACGGAATTCGAGCTC-3’ 
MINX E2 rev 5’-GATCCCCACTGGAAAGACC-3’ 
BamHI-TEV 5’-GATCCTTGAGAATTTGTATTTTCAGGGTGG-3’ 
TEV-EcoRI 5’-AATTCTACCCTGAAAATACAAATTCTCAAG-3’ 
GST-fwd 5'-ATATAGCATGGCCTTTGCAG-3'  
TEV-rev 5'-CCTGAAAATACAAATTCTCAAG-3'  
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KpnI-GST-fwd 5'-AATTGGTACCTCCCCTATACTAGGTTATTG-3'  
G231A-M235V-
rev 
5’-ATTCCACCACCGCCTGAACTGCATTCTTCCT-3’ 
G231A-M235V-
fwd 
5’-AGGAAGAATGCAGTTCAGGCGGTGGTGGAAT-3’ 
V104A-rev 5’-CCCCTGATGTGGGCAACTGGGGA-3’ 
V104A-fwd 5’-TCCCCAGTTGCCCACATCAGGGG-3’ 
A6.1 5’-AATACGACTCACTATAGGGGAATGTACACAG 
AAGTAGGAAACACAGAGA-3’ 
A6.2 5’-TCTCTGTGTTTCCTACTTCTGTGTACATTCCCCT 
ATAGTGAGTCGTATT-3’ 
B1.1 5’-AATACGACTCACTATAGGGTATTTTTTCTGCAGT 
CACCGGCTGCCAACA-3’ 
B1.2 5’-TGTTGGCAGCCGGTGACTGCAGAAAAAATAC 
CCTATAGTGAGTCGTATT-3’ 
B2.1 5’-AATACGACTCACTATAGGGTAATCTGCACCAA 
CTGGAGATCAGAAACCA-3’ 
B2.2 5’-TGGTTTCTGATCTCCAGTTGGTGCAGATTACCC 
TATAGTGAGTCGTATT-3’ 
B3.1 5’-AATACGACTCACTATAGGGAAAAAATTTTAACC 
ACAACAAAAAAAAAAT-3’ 
B3.2 5’-ATTTTTTTTTTGTTGTGGTTAAAATTTTTTCCCTA 
TAGTGAGTCGTATT3’ 
B4.1 5’-AATACGACTCACTATAGGGCAGCTCAGAGGCA 
CACAGTTACCTGCTGCC-3’ 
B4.2 5’-GGCAGCAGGTAACTGTGTGCCTCTGAGCTGCC 
CTATAGTGAGTCGTATT-3’ 
B5.1 5’-AATACGACTCACTATAGGGCGTAGTGGGGCCA 
CTGGCACACCTCATACC3’ 
B5.2 5’-GGTATGAGGTGTGCCAGTGGCCCCACTACGC 
CCTATAGTGAGTCGTATT-3’ 
B6.1 5’-AATACGACTCACTATAGGGGGAGACACGCACAC 
GGAGCGCTACACAGCC-3’ 
B6.2 5’-GGCTGTGTAGCGCTCCGTGTGCGTGTCTCCC 
CCTATAGTGAGTCGTATT-3’ 
B7.1 5’-AATACGACTCACTATAGGGAAGCACCGCACCAC 
CGCACTGCAGCACATA-3’ 
B7.2 5’-TATGTGCTGCAGTGCGGTGGTGCGGTGCTTC 
CCTATAGTGAGTCGTATT-3’ 
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B8.1 5’-AATACGACTCACTATAGGGGGAGGGACACTAC 
CCACTTCATACACCTTT-3’ 
B8.2 5’-AAAGGTGTATGAAGTGGGTAGTGTCCCTCCCCC 
TATAGTGAGTCGTATT-3’ 
B3.1Mut 5’-AATACGACTCACTATAGGGAAAAAATTTTAACCG 
CGACAAAAAAAAAAT-3’ 
B3.2Mut 5’-ATTTTTTTTTTGTCGCGGTTAAAATTTTTTCCC 
TATAGTGAGTCGTATT-3’ 
Mut 1 B7.1 5’-AATACGACTCACTATAGGGAAGCGCGGCACC 
ACCGCACTGCAGCACATA-3’ 
Mut 1 B7.2 5’-TATGTGCTGCAGTGCGGTGGTGCCGCGCTTCC 
CTATAGTGAGTCGTATT-3’ 
Mut 1-2 B7.1 5’-AATACGACTCACTATAGGGAAGCGCGGCGCC 
GCCGCACTGCAGCACATA-3’ 
Mut 1-2 B7.2 5’-TATGTGCTGCAGTGCGGCGGCGCCGCGCTTCC 
CTATAGTGAGTCGTATT-3’ 
Mut 3 B7.1 5’-AATACGACTCACTATAGGGAAGCACCGCACCAC 
CGCACTGCAGCGCGTA-3’ 
Mut 3 B7.2 5’-TACGCGCTGCAGTGCGGTGGTGCGGTGCTTC 
CCTATAGTGAGTCGTATT-3’ 
Mut 2 B7.1 5’-AATACGACTCACTATAGGGAAGCACCGCGCCGC 
CGCACTGCAGCACATA3’ 
Mut 2 B7.2 5’-TATGTGCTGCAGTGCGGCGGCGCGGTGCTTCCC 
TATAGTGAGTCGTATT-3’ 
B6B7.1 5’-AATACGACTCACTATAGGGGGAGACACGCACA 
CGGAGCGCTACACAGCCAGAAGCACCGCACCACC 
GCACTGCAGCACATA-3’ 
B6B7.2 5’-TATGTGCTGCAGTGCGGTGGTGCGGTGCTTCTG 
GCTGTGTAGCGCTCCGTGTGCGTGTCTCCCCCTAT 
AGTGAGTCGTATT-3’ 
B7.1 5’-AATACGACTCACTATAGGGAAGCACCGCACCACC 
GCACTGCAGCACATA-3’ 
B7.2 5’-TATGTGCTGCAGTGCGGTGGTGCGGTGCTTCCCT 
ATAGTGAGTCGTATT-3’ 
B7(4).1 5’-AATACGACTCACTATAGGGAAGCACCGCACCACCC 
TGCCACATA-3’ 
B7(4).2 5’-TATGTGGCAGGGTGGTGCGGTGCTTCCCTATAGTG 
AGTCGTATT-3’ 
B7(13).1 5’-AATACGACTCACTATAGGGAAGCACCGCACCACC 
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TGGCACTGCAGTGCACATA-3’ 
B7(13).2 5’-TATGTGCACTGCAGTGCCAGGTGGTGCGGTGCT 
TCCCTATAGTGAGTCGTATT-3’ 
 
 
2.1.11 RNA oligonucleotides 
 
5’-Biotin-(CA)32-3’ Xeragon 
 
 
2.1.12 Other materials  
 
Eppendorf tube, 1.5 ml, 2 ml Eppendorf 
Falcon tube Greiner 
FuGene transfection reagent Roche 
Glutathione agarose 4B Macherey-Nagel 
HeLa cell nuclear extract 4C Biotech 
Hybond ECL nitrocellulose membrane GE Healthcare 
Lumi-Light western blotting substrate Roche 
Neutravedin agarose resin Thermo Scientific 
Nickel-nitrilotriacetic acid (Ni-NTA) agarose QIAGEN 
Pasteur pipet Roth 
Roti-block  Roth 
Superdex 200 Sigma 
X-ray film Kodak X-OMAT 
 
 
2.2 Methods 
 
 
2.2.1 DNA cloning 
 
2.2.1.1 Preparation of plasmid DNA 
 
Plasmid DNA was isolated from overnight culture using the QIAprep Spin Miniprep 
Kit (QIAGENE) according to the manufacturer’s instruction. The concentration of 
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the plasmid DNA was determined by UV light absorption at 260 nm using a 
spectrophotometer (Eppendorf). 
 
2.2.1.2 Agarose gel electrophoresis 
 
The separation of DNA fragments according to their size was performed using gels 
with 1-2 % agarose in TBE buffer (100 mM boric acid; 100 mM Tris; 2 mM EDTA 
pH 8,8) with ethidium bromibe (1:20.000 dilution). Samples were mixed with 
appropriate amount of 6x DNA loading buffer (30% (v/v) glycerol; 0,025% (w/v) 
bromphenol blue) before loading. Gels were run at 130V. The bands were 
visualised with gel documentation system (SynGene). 
 
2.2.1.3 DNA extraction from agarose gels 
 
DNA bands were excised with a scalpel, transferred to sterile Eppendorf vials, 
weighed and purified with QIAprep Gel Extraction Kit columns (QIAGEN) following 
the instructions of the manufacturer. 
 
2.2.1.4 DNA cleavage with restriction enzymes 
 
Restriction digests were performed using the buffer system and temperature 
recommended by the manufacturer (New England Biolabs). 1-5 units of enzyme per 
1 µg DNA were used. Incubation time was at least 1 hour. Completion of the 
digests was analysed on agarose gels (2.2.1.2). DNA was purified by gel extraction 
or phenolisation. 
 
2.2.1.5 Dephosphorylation of DNA 
 
In order to prevent self-ligation of the linearised by endonuclease digestion DNA 
plasmid vector dephosphorylation of the 5’-terminus was performed. 10 µg of the 
vector DNA was incubated with 1x SAP buffer and 1 U/µl SAP in a total volume of 
50 µl for 30 min at 37ºC. The enzyme was heat inactivated afterwards by incubation 
at 65ºC for 15 min. 
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2.2.1.6 Ligation 
 
DNA fragments were ligated with T4 DNA ligase (New England Biolabs) in a 
volume of 10 µl at room temperature for 2 hours or at 16ºC overnight using the 
buffer system supplied by the manufacturer. 
 
2.2.1.7 Transformation of E.coli cells 
 
For transformation, chemically competent cells were thawed on ice. 100 µl of the 
cells were mixed with 100 ng of plasmid DNA or 10 µl of ligation mixture and 
incubated on ice for 30 min. The mixture was placed at 42ºC for 40 s, then on ice 
for 5 min. After addition of 500 µl LB medium and 60 min incubation at 37oC, the 
mixture was plated on pre-warmed LB agar plates with 100 µg/ml ampicillin. The 
plates were incubated overnight at 37ºC. If blue/white selection was carried out for 
selecting recombinants, 40 µl of X-gal stock solution and 40 µl of IPTG solution 
were spread on LB plates before the transformation cultures were plated out. 
 
2.2.1.8 PCR amplification of DNA  
 
A standard PCR reaction to amplify DNA from a plasmid template contained 1-10 
ng of plasmid DNA, forward and reverse primers (0,5 µM each), dNTPs (200 µM), 
1x Taq polymerase buffer, 1 mM MgCl2 and 1U Taq polymerase in total volume of  
25 µl. When the amplification was made for cloning purposes, a high-fidelity 
polymerase, e.g. Pwo DNA polymerase was used instead of Taq polymerase. The 
amplification was carried out in a GeneAmp PCR System 9700 thermocycler under 
the following conditions: initial denaturation for 2-4 min at 94ºC; 25-35 cycles of 15-
30 sec at 94ºC, annealing at the Tm of the primers pair, extension of 1 min per 1 kb 
at 72ºC. After the last cycle the reaction was held for 5-10 min at the extension 
temperature to allow completion of amplification of all products. 
 
 
2.2.2 Generation of hnRNP L and hnRNP LL mutants 
 
pGEX-5x-2-hnRNP L-FLAG. The EcoRI-XhoI restriction fragment containing the 
full-length cDNA for hnRNP L was released from pFAST-BAC Htb-hnRNP L and 
cloned into pGEX-5x-2 expression vector. To introduce the FLAG-tag the PCR 
fragment amplified form pGEX-5x-2-hnRNP L vector with 5’-KpnI and FLAG-L 
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primers was digested with KpnI and EcoRI restriction enzymes and subcloned into 
pGEX-5x-2-hnRNP L vector. 
pGEX-5x-2-hnRNP LL-FLAG. Total RNA was isolated from HeLa cells and reverse 
transcribed with oligo(dT) primers. The hnRNP LL ORF amplified with specific 
hypo-1 and hypo-2 primers was used as a template for amplification of protein 
coding region with hypo-3 and hypo-4 primers. After EcoRI and SalI restriction the 
PCR fragment was cloned into pGEX-5x-2 expression vector. The insertion of 
FLAG-tag was done as for pGEX-5x-2-hnRNP L-FLAG vector with specific primers: 
LL-KpnI and LL-FLAG. 
The deletion mutants of hnRNP L and hnRNP LL were generated by replacement of 
restriction fragments of cloned wild-type hnRNP L and hnRNP LL cDNA with PCR 
amplified fragments. 
TEV cleavage site was introduced in pGEX-5x-2-L-FLAG construct and its deletion 
derivatives by replacement of the DNA fragment between EcoRI and BamHI 
restriction sites of the initial constructs with annealed and EcoRI-BamHI cut oligos 
containing TEV cleavage site (TEV-EcoRI / BamHI-TEV). 
For V104A, V225A, G231A-M235V mutants, two steps of PCR amplification were 
employed. First, wt hnRNP L cDNA was amplified in separate reactions with oligo 
pairs for V104A: L-Full-FP/ V104A-rev and V104A-fwd/ L-KpnI-RP, for V225A: L-
Full-FP/ V225A-rev and V225A-fwd/ L-KpnI-RP, for G231A-M235V: L-Full-FP/ 
G231A-M235A-rev and G231A-V235M-fwd/ L-KpnI-RP. Each combination of PCR 
products, which have a 20 bp overlap, were gel-purified and used in equimolar 
amounts for second PCR amplification with oligos L-Full-FP/ L-KpnI-RP for all 
constructs. The PCR products were purified and digested with EcoRI and KpnI 
restriction enzymes and subcloned into corresponding sites of pGEX-5x-2-TEV-
hnRNP L-FLAG. 
All subcloning steps were carried out using E.coli J109M. All constructions were 
confirmed by sequence analysis (SeqLab, Göttingen). 
 
 
2.2.3 Expression and purification of proteins in E.coli 
 
2.2.3.1 GST-tagged hnRNP L, hnRNP LL and their derivatives 
 
To express GST-tagged hnRNP L, hnRNP LL and threir mutant derivates, the 
expression constructs were transformed into E.coli BL21 Star cells. Bacteria were 
grown in 400 ml of LB medium, containing ampicillin (100 µg/ml) to OD600=0,6. The 
expression of recombinant proteins was induced by 0,1 mM IPTG overnight. 
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Harvested bacteria were subjected to one freeze/thaw cycle at -80ºC and 
resuspended in 10 ml Extraction Buffer (50 mM Tris-HCl, pH 8,5; 100 mM NaCl;  
1 mM EDTA; 1 mM DTT; protease inhibitor cocktail, Roche). After incubation on ice 
for 20 min with 1 mg/ml of lysozyme, the cell suspension was sonicated 3 times by 
pulses of 30 sec at 50% amplitude (Branson sonifier model B-15), and cellular 
debris was removed by centrifugation for 30 min at 14.000 rpm at 4ºC. The 
supernatant was incubated 30 min on a rotating wheel at 4ºC, with glutathione 
beads (200 µl of 50% bead slurry, GE Healthcare) pre-equilibrated in a 1:1 ratio in 
Extraction Buffer. Beads were washed 4 times for 5 min on a rotating wheel at RT 
with Extraction Buffer, followed by elution of recombinant GST-proteins with 200 µl 
of Elution Buffer (50 mM Tris-HCl pH 8,5; 100 mM NaCl; 1 mM EDTA; 1 mM DTT; 
protease inhibitor cocktail (Roche); 30 mM reduced glutathione). Aliquots of each 
elution fraction were separated on 10% SDS-PAGE and stained by Coomassie 
Blue. Fractions containing recombinant GST-proteins were collected, dialysed 
against Buffer D (20 mM HEPES pH 8,0; 100 mM KCl; 0,2 mM EDTA pH 8,0; 20% 
glycerol; 15 mM MgCl2) and protein concentration was estimated on Coomassie 
Blue stained SDS-PAGE (2.2.8 and 2.2.9) , using BSA (Biolabs) as a standard.  
In order to remove GST tag the TEV cleavage was performed. GST-tagged proteins 
bound to glutathione beads were incubated with TEV protease at 4ºC overnight in 
TEV cleavage buffer (10 mM Tris-HCl pH 8,0; 150 mM NaCl; 0,1% NP-40; 0,5 mM 
EDTA; 1 mM DTT). The supernatant was collected and dialysed against buffer D. 
 
2.2.3.2 His-tagged hnRNP L 
 
To express His-tagged hnRNP L pQE30-hnRNP L construct was transformed into 
BL21 Star E.coli strain. Single colony was then inoculated into 4 ml of LB medium 
and grown overnight. The overnight culture was inoculated into 400 ml of fresh LB 
medium containing ampicillin (100 µg/ml) and incubated at RT to OD600=0,6. For 
induction of the protein expression 1 mM of IPTG was added and cultured overnight 
at RT. After the induction cells were harvested by centrifugation for 15 min at 4000 
rpm. The recombinant His-tagged hnRNP L protein was purified over Ni-NTA beads 
according to the manufacturer’s instruction (QIAexpressionist, QIAGEN). 
 
 
2.2.4 Generation and purification of recombinant baculovirus-expressed His-
tagged hnRNP L 
 
Recombinant baculoviruses are widely used for the production of high levels of 
properly post-translationally modified, biologically active and functional recombinant 
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proteins. Baculovirus expression system based upon the ability to propagate 
AcMNPV (Autographa californica multiple nuclear polyhedrosis virus) in insect cells. 
The heterologous genes are placed under transcriptional control of the strong 
AcNPV polyhedron promoter, thus the recombinant protein is expressed in place of 
the naturally occurred polyhedron protein. Since baculoviruses are non-infectious to 
vertebrates, they are safer to work with than other mammalian viruses (Inceoglu et 
al., 2001). The recombinant baculovirus expressing hnRNP L was made using the 
Bac-to-Bac baculovirus expression system (Invitrogen, USA) according to the 
manufacturer’s instructions. It is a rapid and efficient method based on site-specific 
transposition. 
A full-length cDNA encoding hnRNP L was cloned into a pFASTBAC vector, and 
the recombinant plasmid was transformed into DH10BAC competent cells which 
contain the bacmid with a mini-attTn7 target site and the helper plasmid. The mini-
Tn7 element on the pFAST-BAC plasmid can transpose to the mini-attTn7 target 
site on the bacmid in the presence of transposition proteins provided by the helper 
plasmid. Colonies containing recombinant bacmids were identified by antibiotic 
selection and blue/white screening, since the transposition results in disruption of 
the lacZα gene. High molecular weight mini-prep DNA was prepared from selected 
E.coli clones containing the recombinant bacmid, and this DNA was then used to 
transfect insect cells. The steps to generate a recombinant baculovirus by site-
specific transposition using the BAC-TO-BAC Baculovirus Expression System are 
outlined in figure 2.1. 
 
2.2.4.1 Infection of insect cells 
 
SF21 cells (2×107) were seeded in a 150 cm2 flask with SF-900 II medium with L-
glutamine and 10% FCS and incubated at 27ºC for 30 min. After the cells were 
attached to the flask, they were infected by 10 µl of viral stock [2×109 plaque 
forming units (pfu)/ml] at a multiplicity of infection (MOI) of 10. Four days after 
infection, infected cells were harvested by centrifugation for 10 min at 500 g, 4ºC. 
 
2.2.4.2 Purification of His-tagged hnRNP L from baculovirus-infected insect cells 
 
The cell pellet from one 150 cm2 flask (2 × 107cells) was resuspended in 4 ml of 
lysis   buffer  (50  mM  NaH2PO4;  300 mM  NaCl;  10 mM  imidazole;  pH 8,0)   and  
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Figure 2.1 Generation of recombinant baculoviruses and gene expression with the BAC-TO-
BAC expression system. 
Promotor (green box) - AcNPV polyhedron promoter, Tn7R and Tn7L indicate transposon 7 
elements, GOI – foreign gene of interest (Invitrogen instruction manual).  
 
 
incubated on ice for 10 min. Then the cell lysate was centrifuged at 10.000 x g at 
4ºC for 10 min to pellet cellular debris and DNA. 50 µl of packed Ni-NTA beads was 
added to cleared lasyte and incubated at 4ºC for 2 h with rotating. The bound Ni-
NTA beads were pelleted by centrifugation at 6,000 rpm for 1 min and washed with 
1 ml of wash buffer (50 mM NaH2PO4; 300 mM NaCl; 20 mM imidazole; pH 8,0) 
four times. The His-tagged protein was eluted with 100 µl of elution buffer (50 mM 
NaH2PO4; 300 mM NaCl; 250 mM imidazole; pH 8.0) four times. The eluates were 
collected and analysed by SDS-PAGE. 
 
 
2.2.5 In vitro transcription 
 
2.2.5.1 Annealing of DNA oligos 
 
 
Two complementary oligonucleotides were mixed at the same molar concentration 
in 2x Annealing Buffer (20 mM Tris-HCl, pH 8; 100 mM NaCl) at a final volume of 
100 µl. The tube was placed in a standard heatblock for 2-5 min at 95ºC. The 
heatblock was turned off and the sample was slowly cooled down. 
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2.2.5.2 Transcription of 32P-labeled RNA 
 
Internal radioactive labeling of RNAs was performed by T7 in vitro transcription. 
Either PCR products or annealed oligos were used as templates for transcription. 
Only in the case of MINX, RNA was transcribed from a linearised plasmid. 2 µl of 
template DNA (100 ng/µl) or 1 µl of plasmid (1 µg/µl) DNA were mixed with 5 µl 5x 
transcription buffer, 2,5 µl 100 mM DTT; 1,25 µl 10 mM ATP; 1,25 µl 1 mM CTP; 
1,25 µl 10 mM UTP; 1,25 µl 10 mM GTP; 1 µl RNase inhibitor; 1 µl [α-32P]CTP (800 
Ci/mmol) and 1 µl T7 RNA polymerase (20 U/µl). DMPC-H2O was added to the final 
volume of 25 µl. For MINX transcription, SP6 RNA polymerase was used. 
Transcriptions were carried out at 37ºC for 2 h. 2 µl RQ1 DNase was added to each 
reaction and incubation continued for 30 min at 37ºC. 
Unincorporated nucleotides were removed from the transcription reactions using 
RNA spin columns following the manufacturer’s instructions (Roche). 
Transcribed RNAs were precipitated with 600 µl ethanol; 20 µl 3M NaAc pH 5,2; 
and 1 µl (20 mg/ml) glycogen. After pelleting, washing and drying, the amount of 
RNA was measured using a scintillation counter and calculated using the following 
formula: 
 
RNA [ng] = CTP cold [µM] x volume of reaction [µl] x %incorporation x 
0,0132  
 
The transcripts were dissolved in an appropriate volume of DMPC-H2O. 
 
2.2.5.3 Gel purification of 32P-labeled RNA 
 
RNA transcripts were separated by denaturing polyacrylamide gel (10% (v/v) 
Acrylamide/Bis (1x TBE, 50% urea); 10% (v/v) APS; 0,001 % (v/v) TEMED) 
electrophoresis. The RNA bands were cut out of the gel and sliced into small 
pieces. RNAs were eluted from the gel by 300 µl of 2× PK buffer overnight at room 
temperature with rotating. The eluate was phenolised with Roti-phenol/chloroform 
and precipitated with 1 µl of glycogen (20 mg/ml) and 900 µl of ethanol. After 
washing and air-drying, the purified RNAs were dissolved in DMPC-treated H2O.  
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2.2.5.4 Transcription without 32P-label 
 
Transcription of RNA was carried out as described above. Only 1,25 µl of 10 mM 
CTP was added since [α-32P]CTP was omitted. After transcription and DNase 
treatment, transcribed RNAs were extracted with 200 µl phenol/chloroform/isoamyl 
alcohol (25:24:1) and then precipitated. After pelleting, washing, and drying, 
transcripts were dissolved in 5 µl of DMPC-H2O. 
 
2.2.5.5 Biotin attachment 
 
3’-end biotinylation of transcribed RNA was done according to the protocol 
(Hartmann et al., 2005). 
 
 
2.2.6 In vitro splicing of pre-mRNAs 
 
2.2.6.1 Splicing reaction 
 
Approximately 10 ng of unlabeled, capped pre-mRNA substrate was incubated with 
30% HeLa nuclear extract in a total volume of 12,5 µl containing 3,2 mM MgCl2; 20 
mM phosphocreatine; 0,5 mM ATP; 2,66 % polyvinyl alcohol; 1,6 U/µl RNaseOUT 
(Invitrogene). Reaction mixtures were incubated for 4 h at 30ºC. 
 
2.2.6.2 Proteinase K treatment 
 
Aliquots of the splicing reaction were mixed with 83,5 µl DMPC-H2O; 100 µl 2x PK 
buffer (200 mM Tris-HCl; 300 mM NaCl; 25 mM EDTA; 2% SDS) and 4 µl PK (10 
mg/ml). Reactions were incubated for 30 min at 37ºC. The RNA was extracted with 
phenol, precipitated, washed, dried and dissolved in 5 µl DMPC-H2O. 
 
2.2.6.3 Analysis of in vitro splicing by RT-PCR 
 
In the RT-PCR assay, 1 µl of RNA was reverse-transcribed in a volume of 15 µl 
with qScript Reverse Transcriptase (Quanta Biosciences) and random hexamer 
primer according to the manufacturer’s protocol to generate DNA. 5 µl of the RT 
reaction was used as template in the PCR assay (2.2.1.8). 10 µl of each PCR 
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reaction was analysed by 2% agarose gel electrophoresis and ethidium bromide 
staining (2.2.1.2). 
 
 
2.2.7 Depletion of hnRNP L from HeLa nuclear extract 
 
HeLa cell nuclear extract was depleted of hnRNP L with a 5’-biotinylated (CA)32 
RNA oligonucleotide and neutravidin-agarose resin. 200 µl neutravidin-agarose 
resin was blocked in 500 ml blocking solution (4 mM HEPES pH 8,0; 0,2 mM DTT; 
2 mM MgCl2; 20 mM KCl; 0,002% (v/v) NP-40; 0,2 mg/ml tRNA; 1 mg/ml BSA; 0,2 
mg/ml glycogen) at 4ºC O/N followed by washing four times with 1 ml of WB 400 
(20 mM HEPES pH 8,0; 1 mM DTT; 10 mM MgCl2; 400 mM KCl; 0,01% (v/v) NP-
40). For each depletion reaction, 20 µl of packed beads were then incubated with 6 
µg of the 5’-biotinylated (CA)32 RNA oligonucleotide in 200 µl of WB 400 for 4 h at 
4ºC with rotation. A mock depletion was done in the absence of RNA 
oligonucleotide. Beads were washed four times with 1 ml of WB 400 and one time 
with buffer D (20 mM HEPES pH 8,0; 100 mM KCl; 0,5 M EDTA; 20% (v/v) glycerol; 
1 mM DTT; 1 mM PMSF), followed by incubation with 200 µl of HeLa nuclear 
extract for 30 min at 30ºC with rotation. Then, the KCl concentration was increased 
up to 600 mM and the incubation continued for 20 min at 4ºC. After removal of the 
neutravidin beads, depleted nuclear extracts were dialysed against buffer D for 2 h 
at 4ºC. 
 
 
2.2.8 Electrophoresis of proteins  
 
Proteins were resolved on denaturing SDS polyacrylamide gels. Two buffers were 
used: 4x stacking gel buffer (0,5 M Tris-HCl pH 6,8; 0,4% (w/v) SDS) and 4x 
separating buffer (1,5 M Tris-HCl pH 8,8; 0,4% (w/v) SDS) to prepare either  
stacking gel (5% acrylamide/bisacrylamide 37,5:1; 1x stacking gel buffer; 200 µl 
APS; 20 µl TEMED in 20 ml) or separating gels (10-12% Acrylamide/bisacrylamide 
37,5:1; 1x separating gel buffer; 100 µl APS; 10 µl TEMED in 10 ml) respectively. 
The proteins were mixed with sample loading buffer (2% SDS; 10% glycerol; 50 
mM Tris-HCl pH 6,8; 0,005% BPB), denatured at 96ºC for 5 min and loaded on the 
gel. Electrophoresis was carried out at 100-130 V in SDS gel running buffer (25 mM 
Tris; 250 mM glycine pH 8,3; 0,1% (w/v) SDS). Gels were subjected to either 
Western blot analysis or Coomassie blue staining. 
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2.2.9 Coomassie staining 
 
To detect the proteins in SDS polyacrylamide gels, coomassie staining was used. 
After electrophoresis the gel was placed in staining solution (0,25% (w/v) 
Coomassie Brilliant Blue R250; 50% (v/v) methanol; 10% (v/v) acetic acid) for 20 - 
30 min at RT. After the incubation the gel was distained with Coomassie blue 
distaining solution (50% (v/v) methanol; 10% (v/v) acetic acid) until background 
became clear. The gel was dried using a vacuum gel dryer. 
 
 
2.2.10 Western blotting  
 
Proteins were resolved on 10 % SDS-PAGE and transferred to PVDF nitrocellulose 
membrane (GE Healthcare) in transfer buffer (50 mM Tris; 380 mM glycine; 20% 
(v/v) methanol; 0,02% (w/v) SDS) for 30 min at 300 mA using a semi-dry transfer 
cell (Bio-Rad). The membrane was blocked for 1 hour in a blocking buffer (1x TBS; 
1x Roti-Block and 0,05% (v/v) Tween) at RT. The primary antibodies were diluted in 
fresh blocking buffer as follows: monoclonal anti-hnRNP L (4D11) AB 1:10.000; 
peptide polyclonal anti-hnRNP L (D-17) AB 1:500; polyclonal anti-hnRNP LL AB 
1:200; monoclonal anti-GAPDH AB 1:10.000 and added to mambrane for 
incubation for 1h at RT. The membrane was washed three times for 10 min in 1 x 
TBST (50 mM Tris-HCl pH 8,0; 150 mM NaCl; 0,05% Tween) and incubated with a 
secondary peroxidase conjugated antibodies diluted in blocking buffer 1:10.000 for 
1 hour at RT. The membrane was subsequently washed three times for 10 min in 
TBST and the bound antibodies were detected by the Lumi-Light ECL system 
according to supplemented protocol. The membrane was then exposed to an X-ray 
film (Kodak X-OMAT) and developed. 
 
 
2.2.11 Electromobility shift assay (band shift)  
 
The different amount of hnRNP L and its mutant derivates were incubated with 4 ng 
of 32P-labeled gel-purified RNA (GSTZ1; (CA)10; (CA)20) in a binding buffer 
containing 20 mM HEPES pH 8,0; 100 mM KCl; 15mM MgCl2; 0,2 mM EDTA pH 
8,0; 20% glycerol; 5 mg tRNA. The total reaction volume was 25 µl. The mixtures 
were incubated at 4ºC for 20 min. 10µl of aliquots was transferred to a new tube 
containing 1 µl of heparin (4 mg/µl). After 5 min heparin treatment at room 
temperature, 1 µl of native RNA gel loading buffer (0.025% (w/v) bromophenol blue; 
30% (v/v) glycerol) was added and the samples were fractionated on a 6% native 
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RNA gel (acrylamide/bisacrylamide 80:1; 1xTBE; 400 µl 10% APS; 40 µl TEMED 
filled up with H2O to 50 ml) for 1h at 23W. Samples were visualised by 
autoradiography. 
 
2.2.12 Filter binding assay 
 
Filter binding assay was carried out as described (Hui et al., 2005). Approximately 
90 fmol of in vitro transcribed 32P-labeled RNA was incubated with different amount 
of hnRNP L and its mutants in a final volume of 50 µl of binding buffer (10 mM Tris-
HCl pH 8,0; 100 mM KCl; 2,5 mM MgCl2; 0,01% NP-40; 10% glycerol; 0,2 mg/ml 
BSA) at RT for 20 min. The reactions were applied onto the pre-incubated with 
washing buffer (10 mM Tris-HCl pH 8,0; 100 mM KCl; 2,5 mM MgCl2) for 30 min 
0,45 µm supported nitrocellulose membrane (Bio-Rad). After washing and air-
drying, the filter was quantified on a PhosphorImager. 
 
 
2.2.13 Gel-filtration of RNA-protein complexes 
 
32P-labeled RNA was denatured for 2 min at 95ºC followed by cooling for 5 min on 
ice. Appropriate amount of His-tagged hnRNP L in buffer D was added to RNA. 
RNA and protein were incubated for 15 on ice. Ger filtration of RNA-protein 
complex was performed using a 1 x 30-cm glass column (Bio-Rad) filled up to 28 
cm with Superdex 200 gel filtration matrix (Sigma) and gel filtration buffer (10 mM 
Tris-HCl pH 8; 100 mM KCl; 2,5 mM MgCl2) at a flow rate of 100 µl/min using a 
peristaltic pump. The eluted fractions (250 µl each) were analysed by denaturing 
RNA gel and autoradiography. 
 
 
2.2.14 Glycerol gradient 
 
32P-labeled 5’-CA cluster or 3’- CA cluster RNAs were incubated with different 
amount of His-tagged hnRNP L at 4ºC for 20 min in Buffer G (20 mM HEPES; 150 
mM KCl; 1,5 mM MgCl2) in the presence of 2,3 µg/µl tRNA and 1,6 U/µl RNasOUT. 
Samples were then applied onto a 10–30% glycerol gradient in 2 ml and centrifuged 
at 44,000 rpm at 4ºC for 4 h, using TLS 50 rotor (Beckman). Fractions were taken 
from the top of tube by using a pipette (10 fractions, 200 µl per fraction). RNAs from 
each fraction were isolated and analysed by denaturing gel and autoradiography. 
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2.2.15 In vitro protein-binding assay 
 
Purified GST-tagged hnRNP L and its mutant derivates were incubated with 100 µl 
packed glutathione Sepharose 4B (GE Healthcare) in TIF buffer (150 mM NaCl; 20 
mM Tris-HCl pH 8,0; 1 mM MgCl2; 0,1% NP40; 10% Glycerol) for 30 min at RT. The 
beads were pelleted and washed four times with TIF buffer followed by incubation 
with 2 µg of recombinant His-tagged hnRNP LL in 500 µl of TIF buffer for 1h at 4ºC. 
The beads were washed four times with TIF buffer and resuspended in SDS 
sample buffer (2% SDS; 80 mM Tris-HCl; 5% β-mercaptoethanol; 15% glycerol; 
0,05% bromphenol blue; pH 6.8) and boiled. The proteins eluted from the beads 
were then fractionated on a 10% SDS-PAGE, transferred to a nitrocellulose 
membrane, and visualised by immunoblot with an anti-His monoclonal antibody 
(Qiagen). 
 
2.2.16 Databases and computational tools  
 
Database / software URL Description Reference 
ClustalW  http://www.ebi.ac.uk/cl
ustalw/index.html 
Multiple sequence 
alignment program for 
DNA or proteins  
(Thompson et al., 
1994)  
Human BLAT Search  http://www.genome.uc
sc.edu/cgi-bin/hgBlat 
Sequence alignment 
tool similar to BLAST  
(Kent, 2002; Kent et 
al., 2002)  
NCBI HomoloGene  
http://www.ncbi.nlm.ni
h.gov/entrez/query.fcg
i?db=homologene 
Automated detection 
of homologs among 
the annotated genes 
of several completely 
sequenced eukaryotic 
genomes  
(Wheeler et al., 2005)  
SMART 
http://smart.embl-
heidelberg.de  
 
Allows identification of 
genetically mobile 
domains and analysis 
of domain 
architectures 
(Schultz et al., 1998; 
Letunic et al., 2002) 
Pfam http://pfam.sanger.ac.
uk  
Database of protein 
families that includes 
their annotations and 
multiple sequence 
alignments 
(Finn et al., 2008) 
SMS (sequence 
manipulation suite) 
http://www.bioinformat
ics.org/sms2/index. 
 
JavaScript programs 
for generating, 
formatting, and 
analysing short DNA 
and protein 
sequences 
(Stothard, 2000) 
RNAfold http://rna.tbi.univie.ac.
at/cgi-bin/RNAfold.cgi  
Prediction of 
secondary structures 
of single stranded 
RNA or DNA 
sequences 
(Hofacker, 2003) 
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3. Results 
 
3.1 HnRNP L and hnRNP LL domain structures 
 
SMART and PFAM databases (Schultz, 1998; Finn et al., 2008) were used in order 
to inspect the domain structure of hnRNP L and its paralog hnRNP LL. The three 
classical RNA recognition motifs (RRM) were identified in both proteins (Fig. 3.1), 
notably RRM4 of both proteins was not identified as an individual domain by the 
SMART computational sequence analysis tools, but it was included into the domain 
structure of hnRNP L and hnRNP LL as a loosely conserved RRM. The amino acid 
sequence analysis also revealed that hnRNP L has an additional glycine-rich region 
at the N-terminal end of the protein and a proline-rich region between RRM2 and 
RRM3. In contrast, hnRNP LL has only a less pronounced glycine-rich region and 
does not have a proline-rich region.  
 
 
Figure 3.1 Domain structures of the hnRNP L and hnRNP LL proteins. 
Schematic representation of the domain structures of hnRNP L (P14866; 589 amino acids) and the 
closely related hnRNP LL protein (Q53T80; 542 amino acids). Four RNA recognition motifs (RRM) 
are represented by the green boxes. The glycine- and proline-rich regions are shown in orange and 
blue, respectively 
 
A comprehensive alignment of the RNA recognition motifs of hnRNP L and hnRNP 
LL with all known RRM containing proteins (Fig. 3.2, only several proteins are 
shown) confirmed that three RRMs, namely 1, 2 and 3 of hnRNP L as well as 
hnRNP LL match the criteria for identifying bonafide RRMs with RRM2 being most 
conserved, whereas RRM4 domains only partially satisfy the criteria. Distinctive 
features of most RRMs are βαββαβ structure and the solvent-exposed aromatic 
residues in the β-3 strand (RNP1) and β1 strand (RNP2), which are conserved in all 
of these RRMs. Although in the RRMs of hnRNP L and hnRNP LL several 
conserved phenylalanine aromatic residues are substituted by leucine, the 
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Figure 3.2 Multiple alignment of selected RRMs of human hnRNP proteins. 
Sequences were aligned using the ClusterW program. Amino acids identical or similar are shaded by dark grey or light grey, respectively. Conserved 
secondary structure elements are indicated above the alignment. RNP1 and RNP2 motifs are marked below the alignment. The asterisk indicates the 
position of a conserved glycine residue important for secondary structure formation.  The numbers on the left of the alignment indicate the first and last 
residues of the respective RRM.  
 
 
β1 β2 β3 β4 α1 α2 
HNRH1_HUMAN/11-90   RRM1  FVVKVRGLPW........SCSADEVQRFFsd......cKIQNGAQGIRFIYT........REGRPSGEAFVELESEDEVKLALKkd......rETMGH--........--RYVEVFKSNN 
HNRH1_HUMAN/111-188 RRM2  GFVRLRGLPF........GCSKEEIVQFFsgl....eiVPNGITLPVDF---........-QGRSTGEAFVQFASQEIAEKALK.........-KHKERI........GHRYIEIFKSSR 
HNRH1_HUMAN/289-364 RRM3  HCVHMRGLPY........RATENDIYNFF.........---SPLNPVRVHIEi......gPDGRVTGEADVEFATHEDAVAAM-.........SKDKANM........QHRYVELFLNST 
HNRH2_HUMAN/11-90   RRM1  FVVKVRGLPW........SCSADEVMRFFsd......cKIQNGTSGIRFIYT........REGRPSGEAFVELESEEEVKLALKkd......rETMGH--........--RYVEVFKSNS 
HNRH2_HUMAN/111-188 RRM2  GFVRLRGLPF........GCSKEEIVQFFsgl....eiVPNGMTLPVDF---........-QGRSTGEAFVQFASQEIAEKALK.........-KHKERI........GHRYIEIFKSSR 
HNRH2_HUMAN/289-364 RRM3  HCVHMRGLPY........RATENDIYNFF.........---SPLNPMRVHIEi......gPDGRVTGEADVEFATHEDAVAAM-.........AKDKANM........QHRYVELFLNST 
HNRPD_HUMAN/97-179  RRM1  WKMFIGGLSW........DTTKKDLKDYF.........SKFGEVVDCTLKLDp.......ITGRSRGFGFVLFKESESVDKVMDqk.....ehKLNGKVI........DPKRAKAMKTKE 
HNRPD_HUMAN/182-261 RRM2  KKIFVGGLSP........DTPEEKIREYF.........GGFGEVESIELPMDn.......KTNKRRGFCFITFKEEEPVKKIMEk........KYHNVGL........SKCEIKVAMSKE 
HNRPF_HUMAN/111-188 RRM1  GFVRLRGLPF........GCTKEEIVQFFsgl....eiVPNGITLPVDP---........-EGKITGEAFVQFASQELAEKAL-.........GKHKERI........GHRYIEVFKSSQ 
HNRPF_HUMAN/289-366 RRM2  HCVHMRGLPY........KATENDIYNFF.........---SPLNPVRVHIEi......gPDGRVTGEADVEFATHEEAVAAMSkd.....raNMQHRYI........---ELFLNSTTG 
HNRPG_HUMAN/8-86    RRM1  GKLFIGGLNT........ETNEKALEAVF.........GKYGRIVEVLLMKDr.......ETNKSRGFAFVTFESPADAKDAAR.........DMNGKSL........DGKAIKVEQATK 
HNRPM_HUMAN/71-149  RRM1  YRAFITNIPF........DVKWQSLKDLVk........EKVGEVTYVELLMD........AEGKSRGCAVVEFKMEESMKKAAE.........VLNKHSL........SGRPLKVKEDPD 
HNRPM_HUMAN/204-281 RRM2  STVFVANLDY........KVGWKKLKEVF.........SMAGVVVRADILED........KDGKSRGIGTVTFEQSIEAVQAIS.........MFNGQLL........FDRPMHVKMDER 
HNRPM_HUMAN/653-729 RRM3  CQIFVRNLPF........DFTWKMLKDKF.........NECGHVLYADIKME........-NGKSKGCGVVKFESPEVAERACR.........MMNGMKL........SGREIDVRIDRN 
HNRPQ_HUMAN/162-241 RRM1  TEIFVGKIPR........DLFEDELVPLF.........EKAGPIWDLRLMMDp.......LTGLNRGYAFVTFCTKEAAQEAVK.........LYNNHEIr.......SGKHIGVCISVA 
HNRPQ_HUMAN/243-325 RRM2  NRLFVGSIPK........SKTKEQILEEFs........KVTEGLTDVILYHQp......dDKKKNRGFCFLEYEDHKTAAQARRr........LMSGKVKv.......WGNVGTVEWADP 
HNRPQ_HUMAN/338-408 RRM3  KVLFVRNLAN........TVTEEILEKAF.........SQFGKLERVKKLKD......-------YAFIHFDERDGAVKAME.........EMNGKDL........EGENIEIVFAKP 
HNRLL_HUMAN/76-150  RRM1  PVVHVRGLCE........SVVEADLVEAL.........EKFGTICYVMMM--........---PFKRQALVEFENIDSAKECVTf........AADEPVYi.......AGQQAFFNYSTS 
HNRLL_HUMAN/167-242 RRM2  KVLLLSIQNP........PITVDVLYTVC.........NPVGKVQRIVIFK.........RNGIQAMVEFESVLCAQKAKAALN.........ALNGADIY.......GCCTLKIEYA 
HNRLL_HUMAN/335-409 RRM3  SVVMVSGLHQl.......KMNCSRVFNLF.........CLYGNIEKVKFMKT........----IPGTALVEMGDEYAVERAVT.........HLNNVKL........FGKRLNVCVSKQ 
HNRLL_HUMAN/454-337 RRM4  CVLHYYNVPL........CVTEETFTKLC.........—EVLTFIKYKVF..........KPSAKTLSGLLEWECKTDAVEALT.........-L-HNYQ........RVNPGSNPYTLK 
HNRPL_HUMAN/102-176 RRM1  PVVHIRGLID........GVVEADLVEAL.........QEFGPISYVVVMPK........-----KRQALVEFEDVLGACNAVNy........AADNQIYi.......AGHPAFVNYSTS 
HNRPL_HUMAN/193-270 RRM2  SVLLFTILNPi......ySITTDVLYTIC.........NPCGPVQRIVIFR-........---KNGVQAMVEFDSVQSAQRAKA.........SLNGADIy......sGCCTLKIEYAKP 
HNRPL_HUMAN/382-456 RRM3  PVLMVYGLDQs.......KMNCDRVFNVF.........CLYGNVEKVKFMKS........----KPGAAMVEMADGYAVDRAIT.........HLNNNFM........FGQKLNVCVSKQ 
HNRPL_HUMAN/501-583 RRM4  NVLHFFNAPL........EVTEENFFEIC.........--GVKRPSSVKVFS........KSERSSSGLLEWESSSDAL..............-L-HNYQ........KNPNGPYPYTLK 
PTBP1_HUMAN/59-143  RRM1  RVIHIRKLPI........DVTEGEVISLG.........LPFGKVTNLLML--........---KGKNQAFIEMNTEEAANTMVNyyts..vtpVLRGQPIyiq...fsNHKELKTDSSPN 
PTBP1_HUMAN/184-260 RRM2  LRIIVENLFY........PVTLDVLHQIF.........SKFGTVLKIITF--........-TKNNQFQALLQYADPVSAQHAKL.........SLDGQNIy......nACCTLRIDFSKL 
PTBP1_HUMAN/337-411 RRM3  SVLLVSNLNPe.......RVTPQSLFILF.........GVYGDVQRVKILFN........----KKENALVQMADGNQAQLAMS.........HLNGHKL........HGKPIRITLSKH 
PTBP1_HUMAN/454-529 RRM4  ATLHLSNIPP........SVSEEDLKVLFs........SNGGVVKGFKFFQ-........---KDRKMALIQMGSVEEAVQALI.........DLHNHDLg.......ENHHLRVSFSKS 
RNP2 RNP1 
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Figure 3.3 Amino acid sequence alignment of hnRNP L orthologues. 
Full-length hnRNP L orthologues from three different organisms were aligned. The accession numbers of each sequence is given in the following: 
heterogeneous nuclear ribonucleoprotein L from Homo sapiens: NP_001524.2; Mus musculus: NP_796275.2; Rattus norvegicus: XP_001068144.1. Each 
RNA recognition motif is labeled by arrows below the alignment. The RNP1 and RNP2 motifs are indicated by black boxes, conserved amino acids in RNP1 
and RNP2 are marked by light pink and blue, respectively. Conserved amino acids are indicated by asterixes. 
3. Results 
 50 
 
hydrophobic interactions which are predominant at these positions are not 
disrupted. 
The RRMs of both proteins, except RRM4, have another important hallmark of 
RNA-recognition motifs – the conserved glycine residues at position 25 which 
seems to be required for the turn into β2 sheet. 
In collaboration with the group of Dr. J. Bujnicki (Warsaw, Poland) secondary 
structures of hnRNP L and LL were predicted. The prediction was based on a 
series of NMR structures of individual RRM domains of PTB in complex with RNA 
(Oberstrass et al., 2005). The model revealed that RRM domains of hnRNP L and 
hnRNP LL have a classical βαββα secondary structure. In addition, both proteins 
have extra β5 sheets in their RRM2 and RRM4. 
Alignment of amino acid sequences of the full-length hnRNP L protein with its 
orthologues from mouse and rat shows strong sequence conservation (97% identity 
of human vs. mouse and 87% identity of human vs. rat) (Fig. 3.3). RRM1 and 
RRM2 show 100% identity, whereas RRMs 2 and 4 have several amino acid 
substitutions in comparison to the mouse and rat domains. The murine hnRNP L 
protein is shorter lacking 31 amino acids at the N-terminus, whereas in the rat 
protein the linker region between RRM2 and RRM3 is 38 amino acids longer than in 
the human and mouse hnRNP L which can result in a different spatial arrangement 
of the two RRMs. 
 
3.2 Design of hnRNP L and hnRNP LL mutant derivatives 
 
HnRNP L and hnRNP LL proteins are composed of several domains including four 
RRMs, the glycine-rich and proline-rich regions. In order to study the contribution of 
each individual domain to the protein’s functions I designed a series of domain 
deletion derivatives based on structurally defined domain boundaries. In addition, 
several mutations were introduced in each individual RNA recognition motif in order 
to disrupt either the RNA-binding ability of a particular domain or inter-domain 
interaction between RRM3 and RRM4 (Fig. 3.4 A, B). 
 
 
3.2.1 Deletion derivatives 
 
Four deletion mutant derivatives were generated for hnRNP L and three for hnRNP 
LL. Either the N-terminal domains RRMs 1 and 2 or the C-terminal domains RRMs 
3 and 4, or RRM1 and RRM4 were deleted to create truncated versions (L/LL∆N, 
L/LL∆C, L-173-502, LL-162-429). In addition, I deleted the glycine-rich region (L∆G) 
of the hnRNP L protein. 
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All constructs contain an N-terminal GST-tag and a C-terminal FLAG-tag allowing 
the usage of both tags for protein purification. In addition, a TEV cleavage site was 
inserted between GST and hnRNP L ORF to remove the GST-tag. 
 
 
3.2.2 Point mutation derivatives 
 
In an attempt to inactivate the RNA-binding properties of RRM1 and RRM2 of 
hnRNP L, single and double point mutations were introduced either in the RNP2 
and RNP1 motifs itself or in the surrounding regions (Fig. 3.4A). Either conserved 
valine at position 104, or valine at position 225, or glycine and methionine at 
positions 231 and 235, respectively, were changed for A or V. The mutants are 
named according to the positions of the introduced point substitutions. Only one 
amino acid substitution, V225A, was made in two different contexts: in the full-
length protein and in the deletion mutant containing RRMs 2 and 3; all other 
mutations were made only in the full-length protein context. All mutants are GST-
tagged at the N-terminus and FLAG-tagged at the C-terminus and carry the TEV 
cleavage site for removal of the GST-tag. 
Our collaborator Prof. F. Allain (Zurich, Switzerland) has shown that RRM3 and 
RRM4 interact with each other despite the long linker between the two RRMs 
(Skrisovska and Allain, 2008). In order to disrupt the inter-domain interaction 
charged amino acid residues were replaced by several hydrophobic side chains. 
The positions of the substitutions are indicated in the Figure 3.4A. These two 
constructs carry a His-tag at the N-terminus. 
 
3.3 RNA-binding activity of hnRNP L, hnRNP LL and their deletion 
derivatives (EMSA) 
 
 
 3.3.1 RNA substrates 
 
Previous experiments including an in vitro SELEX approach and various 
biochemical assays determined the binding specificity of hnRNP L and hnRNP LL 
(Hui et al., 2005; Topp et al., 2008). It has been shown that both proteins bind with 
high affinity to two types of RNA substrates: CA-repeat and CA-rich sequences. 
In binding assays I used CA-repeat RNAs of different length: (CA)10 and (CA)20 
RNAs as well as CA-rich RNA: GSTZ1. As a negative control I used an unspecific 
RNA substrate derived from pcDNA3 vector: GSTZ1-substitution carrying no high-
score binding motifs for hnRNP L. 
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Figure 3.4 Generation of hnRNP L and hnRNP LL mutant proteins. 
Schematic diagram of the domain structure of hnRNP L (A), hnRNP LL (B) derivatives. The 
numbers below each construct depict amino acid positions; numbers above indicate amino acid 
substitutions. RNA recognition motifs are marked as green boxes, the glycine-rich and proline-rich 
regions are shown as orange and blue boxes, respectively. 
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Figure 3.5 RNA binding substrates. 
List of RNA substrates used for EMSA and filter binding assays. Number 1 and 2 are CA-repeat 
RNAs of 20 and 40 nucleotides in length, respectively. Number 3 is a CA-rich RNA GSTZ1 of 44 
nucleotides and an unspecific RNA of the same length. Numbers 4 and 5 are CU- and UCUU-repeat 
RNAs of 20 and 24 nucleotides, respectively. The underlined sequences represent hnRNP L high-
score binding motifs as determined by SELEX. 
 
 
The (CU)10 and (UCUU)6 repeat RNAs were used to test the change in substrate 
specificity of hnRNP L upon the introduction of several amino acid substitutions in 
one of the RNA-binding motifs (Fig. 3.5) 
 
 
3.3.2 Identification of the domains of hnRNP L and hnRNP LL critical for CA-
repeat RNA-binding activity 
 
 
In order to test the requirement of individual RRMs of hnRNP L and hnRNP LL for 
binding to CA-rich RNA, I performed Electromobility shift assays (EMSA) with full-
length proteins and their truncated derivatives (Fig. 3.6). 
The (CA)10 and (CA)20 substrates were internally labeled with [α32P] CTP via T7 in 
vitro transcription. A constant concentration of RNA substrate was incubated with 
increasing amounts of recombinant GST-tagged hnRNP L or its deletion mutant 
derivatives. After incubation the samples were treated with heparin to prevent non-
specific association. Formed complexes were resolved on a native polyacrylamide 
gel and detected by autoradiography. 
As shown in Fig 3.6A the full-length protein binds to (CA)10 repeat RNA very 
efficiently (lanes 1-5). Results with deletion mutants demonstrated that the binding 
affinities of full-length hnRNP L and hnRNP L∆C (lanes 6-10) are comparable, 
indicating that RRM1 and RRM2 are most important for binding of CA-repeat RNA. 
Mutant protein hnRNP L173-502 consisting of RRM2 and RRM3 showed a reduced 
binding  affinity  to  (CA)10 repeat  RNA  (lanes  16-19).  Interestingly,  hnRNP  L∆N  
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mutant which includes only RRM3 and RRM4 showed no binding to (CA)10 repeat 
RNA substrate (lanes 11-15). EMSA with the individual RRMs showed no 
detectable binding (data not shown), suggesting the importance of the combined 
action of at least two RRMs for efficient binding to CA-repeat RNA. 
The EMSA with (CA)20 repeat RNA and hnRNP L deletion derivatives (Fig. 3.5B) 
confirmed the observed results with (CA)10 repeat RNA, indicating that two-domain 
combinations (RRM1/2, RRM2/3) are sufficient for efficient binding to CA-repeat-
containing RNA. In contrast, the C-terminal domains (RRM3/4) did not show any 
RNA-binding activity (data not shown). 
The band shift assay with hnRNP L173-502 mutant and (CA)20 RNA (Fig. 3.6B, 
lanes 13-18) indicated that deletion of RRM1 and RRM4 slightly reduced binding 
and produced an aberrantly shifted complex that remained in the gel slot. This 
might be due to abnormal aggregation of this particular mutant. 
Interestingly, both mutant proteins hnRNP L∆C and hnRNP L173-502 consisting of 
RRM2 and RRM1 or RRM3, respectively, showed a comparable reduction of 
binding affinity to (CA)20 repeat RNA (lanes 7-18), suggesting that RRM1 and 
RRM3 might play similar roles in binding, probably in stabilisation of the RNA-
protein complex. 
The results of EMSA with full-length hnRNP L and two different CA-repeat RNAs 
[(CA)10 vs. (CA)20] indicated that two CA-repeat sequences of the different length 
are bound with different affinity by hnRNP L (Fig. 3.6 panel A: lanes 1-5; panel B: 
lanes 1-6), demonstrating that a CA-repeat element with the length of 20 
nucleotides might be too short to interact optimally. Indeed, increase of the 
substrate length up to 40 nucleotides optimised the binding affinity, but an increase 
up to 64 nucleotides (data not shown) did not enhance the binding affinity further. 
Thus, I conclude that the minimal target site required for maximal affinity of a single 
molecule of hnRNP L is around 40 nucleotides. 
In the case of hnRNP LL and its deletion derivatives EMSA (Fig. 3.6C) 
demonstrated that full-length protein binds to (CA)10 repeat RNA with high binding 
affinity (lanes 1-3), comparable with hnRNP L, but deletion mutant derivatives 
completely lost their binding activity. No complexes could be detected (lanes 3-12) 
for the mutants, except hnRNP LL162-429 where binding affinity was very low. 
The band shift assay with GST protein (Fig. 3.6C, lanes 13-14) confirmed that the 
shifts observed were not due to unspecific association of the GST-tag of all tested 
proteins with the RNA substrates. 
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Figure 3.6 Analysis of binding of hnRNP L and hnRNP LL deletion derivatives to CA-repeat 
RNAs by EMSA. 
Increasing amounts of hnRNP L and its deletion mutants (A, B) as well as hnRNP LL and its 
deletion mutants (C) were incubated with 32P-labeled (CA)10 (A,C) or (CA)20 RNA (B), analysed on a 
native polyacrylamide gel and visualised by autoradiography. The protein concentration is given 
above each gel. Positions of resulting RNA-protein complexes and free RNA are indicated on the 
left. The EMSA with GST protein serves as a negative control (C, lanes 13-14). 
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3.3.3 Identification of the domains of hnRNP L and hnRNP LL critical for 
binding activity to CA-rich RNA 
 
In order to investigate the ability of hnRNP L and hnRNP LL mutant proteins lacking 
several RRMs to bind to a CA-rich substrate I performed electromobility shift assay 
with CA-rich RNA GSTZ1 labeled by in vitro transcription with [α32P] CTP (Fig. 3.7). 
I determined that full-length hnRNP L bound to GSTZ1 RNA with high affinity (Fig. 
3.7A, lanes 1-4), although it was slightly reduced compared with the binding to CA-
repeat RNAs. The removal of the N-terminal RRMs 3 and 4 domains caused a 
significant reduction in binding affinity to GSTZ1 RNA (Fig. 3.7A, lanes 5-8), 
suggesting that the presence of only two domains RRM1 and 2 is not enough for 
high-affinity binding to CA-rich elements. The mutant L∆N with RRMs 1 and 2 
deleted completely lost the ability to bind GSTZ1 RNA (Fig. 3.7A, lanes 9-12). The 
deletion of RRMs 1 and 4 resulted in a decrease of binding to GSTZ1 RNA (Fig. 
3.7A, lanes 13-18) compared to the L∆C mutant. 
EMSA with hnRNP LL deletion derivatives and CA-rich GSTZ1 RNA (Fig. 3.7B) 
indicated that the full-length protein bound to GSTZ1 (Fig. 3.7B, lanes 1-4) with low 
binding affinity and deletion mutant proteins did not form detectable complexes with 
GSTZ1 RNA (Fig. 3.7B, lanes 5-16). 
 
 
3.3.4 RRM2 of hnRNP L is primarily responsible for high-affinity RNA binding 
 
 
My previous band shift experiments indicated that the high-affinity RNA binding by 
hnRNP L appears to require a combination of two RRMs (1/2 or 2/3), with RRM2 
being present in both variants. I decided to test the function of hnRNP L RRM2 in 
RNA binding by introducing a single point mutation in RRM2 in a truncated two-
domain context hnRNP L173-502 (Fig. 3.4A). The amino acid valine at position 225 
was predicted to be responsible for the recognition of high-score binding motif by 
RRM2 although it is located neither in RNP1 nor in RNP2, but upstream of RNP1. 
Taking in to account that the predicted secondary structure of hnRNP L was based 
on PTB structure and PTB has isoleucine at the same position, was decided to 
change V225 of hnRNP L to either isoleucine or alanine. The binding to three 
different substrates was investigated using band shift assays. Specific RNA binding 
was assessed by utilising an (CA)10 repeat RNA substrate (Fig. 3.8A). Altered 
binding specificity was measured with (CU)10 and (UCUU)6 repeat RNAs (Fig. 3.8B, 
C, respectively). 
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Figure 3.7 Analysis of binding of hnRNP L and hnRNP LL deletion derivatives to CA-rich RNA 
by EMSA. 
Constant amount of 32P-labeled GSTZ1 RNA was incubated with increasing amounts of hnRNP L 
deletion mutants (A) and hnRNP LL deletion mutants (B). Protein-RNA complexes and unbound 
RNA were separated by electrophoresis on a native polyacrylamide gel and visualised by 
autoradiography. The protein concentrations are given above each gel. Positions of resulting RNA-
protein complexes and free RNAs are indicated on the left and right. 
 
 
In this experiment, a fixed amount of radiolabeled RNA was incubated with 
increasing amounts of hnRNP L173-502, hnRNP L173-502(V225I), hnRNP L173-
502(V225A) as well as with full-length hnRNP L and PTB. Protein/RNA complexes 
were resolved by gel electrophoresis. 
HnRNP L173-502 bound to CA-repeat RNA with high affinity which corresponds to 
results previously observed (Fig. 3.6A, lanes 1-6). The association of two proteins 
bearing amino acid substitutions (V225I and V225A) with (CA)10 RNA was 
completely  abolished  (Fig. 3.8A, lanes 7-17), indicating the important role of valine  
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at position 225 for CACA motif recognition by RRM2 and the essential role of the 
whole RRM2 domain for high-affinity binding to RNA. 
Since in hnRNP L173-502(V225I) the substitution was made based on PTB 
alignment and Val was changed to Ile, we suggested that this mutation might 
possibly change the substrate specificity of the mutated protein towards the 
recognition of PTB specific motifs: CU and UCUU. 
In order to test this hypothesis, I performed EMSA with 32P-labeled (CU)10 (Fig 
3.8B) and (UCUU)6 (Fig. 3.8C) RNAs and mutant proteins as described above. 
Expectedly, the full-length hnRNP L and hnRNP L173-502 did not show any binding 
activity with either RNA substrates (Fig. 3.8B and C, lanes 1-6), confirming the 
protein’s preference for CACA motifs as a substrate. HnRNP L173-502(V225I) and 
hnRNP L173-502(V225A) (Fig. 3.8B and C, lanes 7-12) did not associate with CU 
and UCUU repeats either, indicating that the substitution of Val at position 225 to Ile 
or Ala did not change the substrate specificity of the protein. 
Interestingly, positive control PTB bound with high affinity only to (UCUU)6 RNA 
(Fig. 3.8B, lanes 14-16 vs. panel C, lanes 13-15), confirming previous observations 
pointing out the UCUU sequence as the preferred RNA binding site of PTB (Perez 
et al., 1997). 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 3.8 RRM2 of hnRNP L is an essential domain for binding activity. 
A fixed amount of 32P-labeled (CA)10 (A), (CU)10 (B) and (UCUU)6 (C) RNAs was incubated with the 
indicated concentration of full-length or mutant hnRNP L proteins and PTB. Protein-RNA complexes 
and unbound RNA were separated on a non-denaturing polyacrylamide gel. Autoradiograms of the 
gels are shown. 
 
 
3.3.5 Unspecific binding activity of hnRNP L and hnRNP LL mutant proteins  
 
Non-specific RNA-binding activity of all hnRNP L and hnRNP LL deletion mutants 
was tested by EMSA with unspecific radiolabeled GSTZ1-substitution RNA. No 
complexes were observed with any of the tested proteins (Fig. 3.9). 
 
 
 
Figure 3.9 HnRNP L and hnRNP LL mutant derivatives show no unspecific binding activity. 
At a concentration of 2µM each protein (wild-type and mutant) was incubated with radiolabeled non-
specific GSTZ1-substitution RNA and then separated on a 6% non-denaturing polyacrylamide gel. 
The position of unbound RNA is indicated on the left. Autoradiogram of the gel is shown. 
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3.4 RNA-binding activity of hnRNP L, hnRNP LL and their mutant 
derivatives (filter binding assays) 
 
Filter binding assays were used to measure the equilibrium dissociation constant of 
hnRNP L mutants (Fig. 3.10) for CA-repeat and CA-rich RNAs in order to assess 
quantitatively the contributions of the individual domains and the mutated residues 
to RNA binding. 
In the experiment, a fixed amount of radiolabeled (CA)20 or GSTZ1 RNAs were pre-
incubated with increasing amounts of hnRNP L mutants and stable binding was 
measured as the radioactivity retained on nitrocellulose membranes. The amount of 
radioactivity in each dot was quantified using a Molecular Dynamics 
Phosphorimager. The dissociation constant (KD) values were estimated by the half-
maximal binding observed in filter binding assay (Fig. 3.10). 
The full-length hnRNP L showed comparable high binding efficiencies to both 
substrates: KD 72nM for (CA)20 vs. KD 119nM for GSTZ1. The binding of the ∆G 
mutant lacking only the N-terminal glycine-rich region to both RNAs was as efficient 
as for the wild-type protein, suggesting that this region does not play an important 
role in CA-repeat or CA-rich RNA binding. The ∆N protein showed no detectable 
binding to either RNAs, thus the KD value could not be calculated. The binding 
affinity of the ∆C for (CA)20 RNA was slightly reduced compared to full-length 
protein (KD for L∆C 180nM), but binding to GSTZ1 was significantly decreased and 
KD value could not be determined. 
The single substitution of valine at position 104 in RNP2 of RRM1 [L(V104A)] 
slightly reduced binding to (CA)20 and GSTZ1 RNA binding (KD 119nM and 140nM, 
respectively), suggesting that this mutation does not directly influence RNA binding 
of the RRM1, or it is compensated by the other RRMs. In contrast, substitution of 
valine at position 225 in the β2-sheet of RRM2 yielded a protein [L(V225A)] that 
bound to CA-repeat RNA with reduced affinity (KD 213nM) and to CA-rich RNA with 
even lower affinity (KD 529nM). Another protein with a double amino acid 
substitution in RNP1 of RRM2 [L(G231A-M235V)] exhibited the same slightly 
reduced affinity for (CA)20 (KD 213nM) and GSTZ1 (KD 169nM) compared to 
L(V104A) protein. 
Interestingly, the amino acid mutations introduced to disrupt inter-domain 
interactions between RRM3 and RRM4 [hnRNP L (V402K-L405D-L556K-L559D) 
and hnRNP L (V402K-L405D-L556K-L559D-G560D)] reduced binding of the 
proteins to (CA)20 (KD 265nM and 230nM, respectively) and strongly reduced the 
binding to GSTZ1 (KD is too low or not measurable). 
The data of the filter binding assays are consistent with the EMSA results and 
demonstrate  synergy   between  the  RRM1  and  RRM2  in binding  to CA repeats. 
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HnRNP L, ∆N and ∆C proteins showed consistent binding to (CA)20 and GSTZ1 
RNA in both assays. 
 
 
 
Figure 3.10 Dissociation constants (KD) of hnRNP L mutant proteins for binding to CA-repeat 
and CA-rich RNAs. 
To compare binding affinities, 90 fmol of labeled (CA)20 or GSTZ1 RNA was incubated with 50, 90, 
180, 360, 720 nM of hnRNP L mutants. All reactions contained 0,2 mg/ml BSA. Bound and free RNA 
were quantified and KD values calculated based on the mean of three independent experiments. The 
GST-tag of mutant proteins used for filter binding had been removed by TEV protease cleavage. 
 
 
3.5 HnRNP L and CA-rich cluster: two elements of autoregulation 
 
3.5.1 CA-rich cluster 
 
In our laboratory we discovered an autoregulation mechanism for hnRNP L protein 
(Rossbach et al., 2009).  By  binding to  a very unusually long CA-rich cluster within  
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its own pre-mRNA, hnRNP L activates the poison exon 6A inclusion, leading to the 
introduction of a premature termination codon and resulting in NMD (Fig. 3.11A).  
The entire region of 2 kb in intron 6 is highly conserved, close to ultraconservation 
in the strict sense (Lareau et al., 2007). The CA-rich cluster is a dense sequence of 
twenty five high-score hnRNP L binding motifs extending over more then 800 nt 
within this highly conserved intronic region (Fig. 3.11B). 
 
A 
B 
 
 
Figure 3.11 CA-rich cluster within a highly conserved region in the hnRNP L gene. 
(A) Exon-intron structure of the human hnRNP L gene. Red bars above the line represent hnRNP L 
binding motifs, with their height corresponding to their score (for how these scores were derived, see 
Hung et al., 2008). (B) Alignment of CA-rich cluster and intron 6 sequences (human (hs) vs. mouse 
(mm)). Numbering refers to nucleotide positions relative to the exon 6A. Exon 6A boxed in blue; the 
two parts of the CA cluster are highlighted by light violet shading, with the CA motifs in red. “STOP” 
codon indicated in red (adapted from Rossbach et al., 2009). 
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3.5.2 HnRNP L binds to CA-rich cluster 
 
Based on the SELEX-derived RNA-binding specificity of hnRNP L, we suggested 
that hnRNP L binds to the CA-rich cluster of its own pre-mRNA with high affinity. 
To test this hypothesis, I performed in vitro pull-down assays (Fig. 3.12). The CA-
rich cluster RNA was in vitro transcribed in two parts: cluster A – the 5’-terminal 
portion (300 nt) and cluster B – 3’-terminal portion (346 nt). Both RNAs were 3’-
biotinylated and incubated in HeLa nuclear extract. HnRNP L binding was then 
assessed by pulling down the biotinylated RNAs, using neutravidin-agarose 
followed by Western blot analysis of the pull-down material with the hnRNP L-
specific monoclonal antibody, 4D11. As specificity controls, a 5’-biotinylated (CA)32 
RNA, cluster ∆ (an unrelated 3’-biotinylated RNA) and beads alone were used. 
As shown in Fig 3.12 both parts of the CA-rich cluster RNA efficiently pulled down 
hnRNP L from HeLa nuclear extract (between 5 and 10% of total hnRNP L at  
70 mM of KCl, lanes 1-3) as well as (CA)32 RNA (lanes 4), whereas pull-down with 
the control cluster ∆ RNA and beads alone did not recover significant hnRNP L 
amount (lanes 5, 6). Together, the data indicate that hnRNP L protein binds 
specifically to the conserved CA cluster. 
In parallel, I tested the binding of the paralog protein hnRNP LL to the CA-rich 
cluster (Fig. 3.12). HnRNP LL could also be specifically pulled down from HeLa 
nuclear extract by both parts of hnRNP L CA cluster (lanes 2, 3) and by (CA)32 RNA 
(lane 4) at 70 mM KCl. 
Next, the salt dependency of CA cluster recognition by hnRNP L and hnRNP LL 
was tested (Fig. 3.12). I incubated biotinylated cluster A, cluster B, cluster ∆, and 
(CA)32 RNAs in HeLa nuclear extract under conditions of different stringency (KCl 
was adjusted to 70, 200, 300 or 400 mM), followed by  neutravidin-agarose 
selection, washing and Western blot analysis with monoclonal anti-hnRNP L (4D11) 
and anti-hnRNP LL antibodies. 
The data presented in Fig. 3.12 illustrated the differences in affinity of hnRNP L and 
hnRNP LL for CA cluster RNA within the salt concentration range mentioned above. 
The strongest association of hnRNP L and hnRNP LL with both parts of the CA 
cluster was detected at 70 mM KCl. At 200 mM KCl the binding of hnRNP L to 
cluster A and B was slightly affected, whereas for hnRNP LL binding was already 
completely abolished. Increase of salt concentration up to 300 mM KCl prevented 
the association of hnRNP L with cluster B RNA and significantly reduced 
association with cluster A RNA. At 400 mM KCl hnRNP L failed to bind of the CA-
rich cluster. Interestingly, binding of hnRNP L and hnRNP LL to (CA)32 RNA was 
stable up to 400 mM KCl and above (data not shown). 
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In summery, biotin pull-down assay of endogenous hnRNP L and hnRNP LL 
revealed salt-dependent binding of both proteins to CA cluster RNA, with hnRNP L 
being more strongly associated with CA cluster. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Salt-dependent binding of hnRNP L and hnRNP LL to CA-rich cluster. 
Biotinylated cluster A and B RNAs (lanes 2 and 3, respectively), (CA)32 RNA (lane 4) and cluster ∆ 
RNA (lane 5) were incubated in HeLa nuclear extract under conditions of different stringency 
(indicated on the right), followed by neutravidin-agarose pull-down. The bound proteins were 
analysed by Western blot with anti-hnRNP L monoclonal antibody (4D11) or anti-hnRNP LL 
antibody. As input 10% of the HeLa nuclear extract was loaded (lane 1). As control, beads were 
incubated with HeLa nuclear extract without RNA (lane 6). 
 
 
3.5.3 Cooperative binding of hnRNP L to CA-rich cluster 
 
The results described above indicate that both parts of the CA cluster bind hnRNP 
L protein with high affinity. Taking into account that cluster A has eleven and cluster 
B fourteenth high-score binding sites (Fig. 3.11B in red) we postulated that each 
single high-score binding motif could bind one molecule of hnRNP L, and that the 
entire CA cluster may bind several hnRNP L molecules, in a cooperative fashion. 
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To investigate this hypothesis, I performed EMSA with fixed amount of 32P-labeled 
cluster A or cluster B RNAs and increasing amounts of baculovirus-expressed His-
tagged recombinant hnRNP L. 
As shown in Fig. 3.13, a shift for both RNA substrates could be detected with 10 – 
20-fold molar excess of recombinant hnRNP L protein (lanes 2-3, 10-11). The three 
bands with different migration behaviour in lane 1 probably represent different 
secondary structures of cluster A RNA. Binding at higher protein concentration 
resulted in the formation of complexes that did not enter the gel. It appeared at the 
lowest protein concentration and became more pronounced as the protein 
concentration was increased. Lack of discrete intermediate complexes suggested a 
high degree of cooperativity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Binding of hnRNP L to CA cluster: evidence for cooperative interactions. 
Radiolabeled cluster A RNA (lanes 1-8) and cluster B RNA (lanes 9-16) were incubated with 
increasing amounts of recombinant hnRNP L. Protein-RNA complexes and unbound RNA were 
analysed on a native acrylamide gel and visualised by autoradiography. The molar excess of protein 
over RNA is given above the gel. Positions of resulting RNA-protein complexes and free RNAs are 
indicated on the left.  
 
 
Being aware that the lack of intermediated complex could result from 
“disproportionation” artefacts (Kleinschmidt et al., 1991), in which there is 
preferential loss of singly occupied complex compared with fully occupied complex 
during electrophoresis and that this could also affect the quantitation of the binding 
affinity, I also analysed protein-RNA complex formation, using glycerol gradient 
centrifugation (Fig. 3.14). 
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The 32P-labeled cluster A or cluster B RNAs were pre-incubated with different 
amounts of recombinant hnRNP L and then separated by centrifugation on a 
glycerol gradient. 
The RNA analysis of the gradient showed that free RNA of cluster A (Fig. 3.14A) 
and free RNA of cluster B (Fig. 3.14B) peaked in the same fractions (2 to 4). Only 
one peak in fractions 5-6 or 6-7 for cluster A and B, respectively, was observed in 
the presence of large excess of recombinant hnRNP L (1:50), indicating the 
sedimentation rate of protein-RNA complex. The further increase in excess of the 
protein did not shift the peak (data not shown). In the presence of small excess of 
recombinant hnRNP L (1:5), two peaks could be detected: first peak in the fractions 
3 or 3-4 for cluster A and B, respectively, corresponding to sedimentation rate of 
free RNA; second peak in the fractions 5-6 or 6-7 for cluster A and B, respectively, 
corresponding to protein-RNA complex. No intermediate complexes were detected. 
The glycerol gradient centrifugation of unrelated cluster ∆ RNA and recombinant 
hnRNP L (1:50 molar excess of the protein) (Fig. 3.14(C)) showed a peak in the 
fractions 2-4, which is similar to the distribution of free cluster A and B RNAs, 
indicating that hnRNP L does not interact specifically with cluster ∆ RNA and that 
the shifts observed for both cluster RNAs were specific. 
Taking together the results from biotin pull-down assay, EMSA and glycerol 
gradient centrifugation analysis I conclude that hnRNP L protein binds to the CA-
rich cluster in a highly cooperative manner. 
 
 
3.5.4 Binding of hnRNP L to short RNAs 
 
In order to characterise hnRNP L binding to cluster B in more detail, I divided this 
region into transcripts of 30 nucleotides (Fig. 3.15A). Each short RNA carries either 
one or two or three high-score binding sites and assayed binding with recombinant 
His-tagged hnRNP L. 
The short RNAs (B1-B8, A6) were internally labeled with [α32P]CTP via T7 in vitro 
transcription. A constant amount of RNA substrate was incubated with increasing 
amounts of recombinant hnRNP L. After incubation the resulting complexes were 
resolved on a native polyacrylamide gel and detected by autoradiography. 
As shown in Fig. 3.15(B) the short RNAs containing a single high-score binding site 
(B3, B4, B5 are shown) failed to form a detectable complex with hnRNP L protein, 
whereas short RNAs with either two (A6) or three (B6-B8) high-score binding motifs 
bound hnRNP L with high affinity. 
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EMSA with short RNAs revealed a general correlation between high-affinity binding 
and amount of binding sites, indicating that high-affinity binding of hnRNP L 
requires at least two high-score motifs within the RNA substrate. 
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Figure 3.14 Glycerol gradient fractionation of protein-RNA complexes. 
32P-labeled cluster A RNA (A) or cluster B RNA (B) was incubated with recombinant hnRNP L 
protein in a molar ratio as indicated on the left. The resulting complexes were separated on a 10-
30% glycerol gradient. 10 fractions were collected from the top to bottom. RNA was recovered from 
each fraction, separated on a 10% denaturing gel and visualised by autoradiography. Arrows 
indicate the sedimentation positions of markers from a gradient run in parallel. Gradient 
centrifugation of cluster ∆ RNA and hnRNP L is shown on panel (C). 
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Figure 3.15 EMSA with hnRNP L and short RNAs. 
(A) Alignment of the CA-rich cluster in intron 6 sequences (human (hs) vs. mouse (mm)). 
Sequences of the human 30mer RNAs used for the binding assay are boxed in black, name of each 
short RNA is indicated above the box. High-score binding motifs coloured in red. (B) 32P-labeled 
short RNAs were incubated with recombinant His-tagged hnRNP L (molar excess indicated above 
each gel). Protein-RNA complexes and unbound RNA were separated on a non-denaturing 
polyacrylamide gel. Autoradiograms of the gels are shown. Position of unbound RNA is indicated on 
the left. 
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To demonstrate in a more controlled assay that the formation of protein-RNA 
complexes depends on the number of high-score binding motifs and not on the 
context of the substrate RNA, I performed EMSA with B7 short RNA and several 
mutant derivatives (Fig. 3.16A). The mutant derivatives were generated by 
introduction of nucleotide substitutions (A or C to G) in either one or two high-score 
binding motifs. 
EMSA was done with 32P-labeled RNA and recombinant hnRNP L protein (Fig. 
3.16). 
The results indicated that wild-type B7 RNA efficiently associated with hnRNP L 
protein (Fig. 3.16B lanes 1-5), whereas the mutations introduced in one of the high-
score binding motifs either strongly diminished (B7M1, lanes 6-10) or completely 
abolished (B7M12, lanes 11-14 and B7M3, lanes 15-19) binding of hnRNP L to 
RNA. 
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Figure 3.16 Mutational analysis of the B7 element. 
(A) The complete sequence of 30-nucleotide B7 RNA and its mutant derivatives. The high-score 
binding motifs are boxed in red, mutated motifs are marked with the star. (B) Band shift experiment 
with B7 mutant derivatives. A fixed amount of 32P-labeled RNA (indicated below the gel) was 
incubated with recombinant hnRNP L protein in molar excess as indicated above the gel. Protein-
RNA complexes and unbound RNA were separated by non-denaturing polyacrylamide gel 
electrophoresis. Autoradiogram of the gel is shown. 
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A new inspection of the sequence of the B7 and its mutants revealed that a single 
high-score binding motif was insufficient for high-affinity RNA binding of hnRNP L. 
RNA with two motifs was bound with very low affinity, demonstrating that the 
presence of two high-score motifs in B7 RNA context were also not optimal for tight 
binding. Only all three motifs allowed strong binding of hnRNP L to the RNA 
substrate. 
Since the binding of hnRNP L to CA cluster occurs in a cooperative manner, we 
propose that by mutation of high-score motifs we disrupted the cooperativity 
between several hnRNP L molecules. 
To understand the complex assembly of hnRNP L and B7 RNA, I performed a gel 
filtration analysis of protein-RNA complexes.  
The 32P-labeled B7 RNA pre-incubated with different amounts of the recombinant 
His-tagged hnRNP L was loaded onto the Superdex 200 gel filtration column and 
eluted under a flow rate of 0,1 ml/min. 
The results (Fig. 3.17) demonstrated that B7 RNA migrated with a retention time 
corresponding to a protein of a molecular mass of approximately 20 kDa (Fig. 3.17, 
fraction 27). However, when B7 RNA was pre-incubated with a 10-fold molar 
excess of hnRNP L for 20 min on ice, the peak was shifted to fraction 20-21 with a 
corresponding Mr of 80 kDa. Under these conditions, hnRNP L and B7 RNA formed 
a complex composed of one molecule of hnRNP L protein with one molecule of B7 
RNA. A further increase of protein concentration did not shift the peak towards 
higher molecular weights. 
Next, I decided to increase the length of RNA and used B6B7 RNA, which is 60 
nucleotides in length, composed of B6 and B7 short RNAs with six high-score 
binding motifs in total. Gel filtration analysis revealed that hnRNP L formed a 
complex with B6B7 RNA that migrated on a gel filtration column with a retention 
time corresponding to a protein of approximately Mr 140 kDa in size (fraction 16). 
Since B6B7 RNA has a Mr 20 kDa, this behaviour in consistent with a complex 
consisting of two hnRNP L molecules bound to one B6B7 RNA. Free B6B7 RNA 
was detected in fractions 19-20. 
The results from the mutational analysis of B7 RNA and gel filtration indicate that a 
single high-score binding motif might be recognised by a single RRM of hnRNP L, 
and the more RRMs are involved in RNA binding the more stable is the association 
of hnRNP L with the RNA. 
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Figure 3.17 Gel filtration analysis of hnRNP L-B7 and hnRNP L-B6B7 RNA complex formation. 
32P-labeled B7 and B6B7 RNA were incubated with hnRNP L protein in a molar excess indicated on 
the left. The complex assembly reactions were performed in a total volume of 150 µl. All reactions 
contained 2 mg/ml tRNA. The samples were loaded onto Superdex-200 gel filtration column and 
eluted under a flow rate of 0,1 ml/min. 33 fractions were collected. Numbers of the fraction are 
indicated below each gel. RNA was recovered from each fraction, separated on a 10% denaturing 
gel and visualised by autoradiography. Positions of the molecular mass standards are indicated on 
the top. Peaks are marked with the arrows. 
 
 
In order to obtain further insight into RNA sequence requirement for stable binding 
of hnRNP L to RNA, I made a new set of mutants to investigate the flexibility of the 
distances between high-score binding motifs. 
Comparison of the distances between high-score binding motifs in A6, B6, B7 and 
B8 short RNAs of the CA cluster revealed that the average length of the spacer is 9 
nucleotides. I chose B7 RNA with a nine-nucleotide spacer and either decreased 
the length of spacer down to four nucleotides [B7(4)] or increased it up to thirteen 
nucleotides [B7(13)] (Fig. 3.18A). 
The 32P-labeled RNAs described above were tested for binding of GST-tagged 
hnRNP L and hnRNP LL using gel shift analysis (Fig. 3.18B). 
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The GST-tagged hnRNP L (lanes 4, 5) efficiently bound to B7 RNA, whereas 
binding of GST-tagged hnRNP LL was much weaker (lanes 2, 3), indicating that B7 
short RNA is not an optimal binding element for hnRNP LL, unlike the full-length 
CA-rich cluster (data not shown). 
Although, some complex formation was seen with both mutant RNAs and GST-
hnRNP L (lanes 9, 10, 14, 15), binding was very weak, indicating that there are tight 
restriction on the length of spacer resulting for optimal binding. 
Since all RRMs of hnRNP L are separated by the linkers of a certain length, the 
high-affinity binding of RRMs to high-score binding motifs within the same RNA 
depend on the distances separating these motifs. 
 
A 
 
 
B 
 
 
 
Figure 3.18 Required length of the spacer for high-affinity binding. 
(A) Sequence of 30-nucleotide B7 RNA and its spacer mutants. The high-score binding motifs are 
boxed in red. (B) EMSA with B7 mutant derivatives. A fixed amount of 32P-labeled RNA (indicated 
below the gel) was incubated with recombinant hnRNP L or hnRNP LL proteins in molar excess 
indicated above the gel. Protein-RNA complexes and unbound RNA were separated by non-
denaturing polyacrylamide gel electrophoresis. Autoradiogram of the gel is shown. Positions of 
resulting RNA-protein complexes and free RNAs are indicated on the left. 
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3.6 HnRNP L and hnRNP LL protein-protein interaction 
 
 
3.6.1 Oligomerisation state of hnRNP L 
 
To examine the oligomeric state of hnRNP L, recombinant His-tagged hnRNP L 
was subjected to gel filtration analysis under non-denaturing conditions (Fig. 3.19). 
This analysis showed that under these conditions, recombinant hnRNP L eluted 
with an apparent molecular mass of 66 kDa (fraction 11) and 132 kDa (fraction 9) 
which corresponds to the expected mass of the monomer and the dimer, 
respectively. Similarly, yeast two-hybrid system and in vitro co-precipitation assays 
indicated that hnRNP L could interact with itself (Kim et al., 2000). Thus, hnRNP L 
exists in solution as a monomer and as a dimer, raising the question of the 
contribution of the homodimerisation to the overall function of hnRNP L. 
 
 
 
 
Figure 3.19 Gel filtration analysis of hnRNP L. 
Recombinant His-tagged hnRNP L was applied to a Superdex-200 gel filtration column and eluted 
under a flow rate of 0,1 ml/min. 20 fractions were collected. The proteins from each fraction were 
precipitated and analysed by SDS-PAGE. The SDS molecular weight markers (M, kDa) and the 
elution pattern of four marker proteins and their sizes are as indicated. Proteins were transferred to a 
PVDF membrane and Western blot was performed to visualise hnRNP L using anti-His antibody. 
Input lane (0,04% of recombinant hnRNP L) is on the left. 
 
 
3.6.2 Mapping of the interaction region of hnRNP L and hnRNP LL 
 
In order to investigate whether hnRNP L and its paralog hnRNP LL are interacting 
with each other I performed GST pull-down experiments (Fig. 3.20). Immobilised 
GST-hnRNP LL was incubated with HeLa nuclear extract (Fig. 3.20A), or 
immobilised GST-hnRNP L was incubated with recombinant His-tagged hnRNP LL 
(Fig. 3.20B). 
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Pull-down experiments revealed strong interaction between hnRNP L and hnRNP 
LL (A, B, lane 2). Neither hnRNP L no hnRNP LL were pulled-down either by GST 
alone or by beads (A, B, lanes 6, 7). Because both hnRNP L and LL are known 
RNA-binding proteins, I next tested whether the interaction between these proteins 
is mediated by RNA. Binding experiments in the presence of RNase A were 
performed. No change in the strength of the binding of hnRNP L to LL and vice 
versa was found (data not shown). This indicates that hnRNP L and hnRNP LL 
interact directly with each other; however the possibility that RNA further regulates 
this interaction cannot be excluded. 
In order to determine the hnRNP L and hnRNP LL domains required for protein-
protein interaction, a series of GST-tagged deletion mutants were tested for the 
ability to interact either with full-length hnRNP L or hnRNP LL (Fig. 3.20). 
As shown in Fig. 3.20B most of the hnRNP L protein was required for the 
interaction with hnRNP LL (lanes 3-5), indicating the presence of multiple 
interacting regions. In the case of hnRNP LL the N-terminal part of the protein 
spanning RRM1 and RRM2 failed to interact with hnRNP L, indicating that the C-
terminal half of hnRNP LL (amino acid 162-542) is involved in the interaction with 
hnRNP L. 
The results for hnRNP L are in agreement with previously observed data, where 
hnRNP L structure was mapped in terms of interaction with other proteins (hnRNP 
E2, K, I, L), demonstrating that the junction sequences between RRM2 and RRM3 
as well as between RRM3 and RRM4 of hnRNP L participate in protein-protein 
interaction (Kim et al., 2000). 
 
3.7 Alternative splicing regulation by hnRNP L and its mutant 
derivatives 
 
3.7.1 SLC2A2 minigene construct 
 
SLC2A2 was identified as an hnRNP L alternative splicing target gene by a 
genome-wide database search (Hui et al., 2005). The gene contains a CA-repeat 
sequence in intron 4 close to the alternatively spliced exon 4 (Fig. 3.21). To 
investigate the influence of these CA repeats on splicing of exon 4, a SLC2A2 
minigene construct was used. It carries exons 3 to 5 with the alternatively spliced 
exon 4 in between. The length of introns 3 and 4 was shortened. In a substitution 
derivative, the CA-repeat element was replaced by a non-specific control sequence. 
It was shown that binding of hnRNP L to the CA-repeat sequence interferes with 
recognition of the 5’-splice site by U1 snRNP, resulting in exon 4 skipping (Heiner et 
al., 2010). 
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Figure 3.20 Mapping of hnRNP L and hnRNP LL domains responsible for protein-protein 
binding. 
Pull-down of endogenous hnRNP L with glutathione-Sepharose beads pre-coated with recombinant 
GST, GST-hnRNP LL or its deletion mutants (A) or His-hnRNP LL with glutathione-Sepharose 
beads pre-coated with recombinant GST, GST-hnRNP L or its deletion mutants (B). Input and bound 
fractions were analysed by SDS-PAGE followed by Western blotting with specific antibodies either 
against hnRNP L (4D11) (A) or anti-His (B). Ponceau S staining of the membranes served as a 
loading control. The SDS molecular weight markers (M, kDa) are indicated on the left, the specific 
protein bands are marked by asterisks. 
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Figure 3.21 Schematic representation of the SCL2A2 gene structure and minigene construct. 
Exons are indicated as black boxes, introns as lines. Exon numbers are labeled. The SLC2A2 
minigene construct carrying constitutive exons 3 and 5 (shown as grey boxes) and alternative exon 
4 (shown as a red box). The length of the introns 3 and 4 was shortened as shown. Alternative 
splicing patterns are indicated by lines below and above the minigene construct. Wild-type (WT) and 
substituted (sub) sequence elements are given with boundaries relative to the 5’ splice site (adopted 
from Heiner et al., 2010). 
 
 
3.7.2 Regulation of exon 4 skipping in vitro by hnRNP L and its mutant 
derivatives: four RRMs required for repressor activity 
 
Previously it was shown that depletion of hnRNP L protein from HeLa nuclear 
extract can affect splicing of SLC2A2 exon 4 by significantly increasing the level of 
its inclusion. Add-back of recombinant hnRNP L protein reversed this effect (Heiner 
et al., 2010). 
The domains of hnRNP L required for splicing repression were examined by testing 
several mutant proteins in the splicing complementation assay. 
To deplete HeLa nuclear extract of hnRNP L protein I took advantage of the tight 
binding of hnRNP L to (CA)32 RNA (Hui et al., 2003b). HeLa nuclear extract was 
incubated with 5’-biotinylated (CA)32 RNA oligonucleotide pre-bound to neutravidin-
agarose beads. After isolation of biotin RNA-bound proteins, the depleted nuclear 
extract was used for in vitro splicing assay. As control, a mock depletion was done 
in the absence of RNA oligonucleotide. 
To test for the efficiency of depletion I performed Western blot analysis with specific 
anti-hnRNP L antibody (4D11) (Fig. 3.22A). The efficiency of hnRNP L depletion 
was 80-90% (compared lanes 1 and 2). GAPDH served as a loading control. Mock 
depletion did not result in a substantial depletion of hnRNP L from HeLa nuclear 
extract (data not shown). 
Next, I confirmed the repressive function of hnRNP L protein on SLC2A2 exon 4 -
inclusion. In vitro transcribed wild-type pre-mRNA was spliced either in hnRNP L- 
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depleted or mock-depleted nuclear extract (Fig. 3.22B). Alternative splicing was 
analysed by semi-quantitative RT-PCR. 
Depletion of hnRNP L but not mock depletion activated splicing of alternative exon 
4. I detected 62% exon inclusion in mock-depleted extract whereas over 90% exon 
inclusion was observed in hnRNP L-depleted extract (Fig. 3.22B, lanes 1, 2). 
Addition of recombinant hnRNP L to the depleted extract repressed splicing to the 
same extent observed in mock-depleted extract (lanes 3-5). I detected 60% of exon 
inclusion at 300 ng of recombinant hnRNP L per 12,5-µl splicing reaction. 
Add-back of hnRNP L lacking the N-terminal glycine-rich region (L∆G) restored the 
inhibitory effect on exon 4 inclusion in a dose-dependent manner (Fig. 3.22B, lanes 
6-8), indicating that the N-terminal glycine-rich region plays no essential role in 
alternative splicing regulation. 
Two hnRNP L deletion mutants (L∆C, L∆N) failed to restore splicing repression 
(Fig. 3.22C, lanes 3-6). Over 90% of exon 4 inclusion compared to hnRNP L-
depleted nuclear extract (lane 2) was observed with addition of 200 ng of each 
protein. 
Add-back of the proteins with amino acid substitutions either in RRM1 or RRM2 
restored the inhibitory effect on exon 4 inclusion, except L-V225A (Fig. 3.22D). The 
level of exon inclusion was decreased to 57 and 62% for L-V104A and L-G231A-
M235V, respectively (lanes 3, 4 and 5, 6). Interestingly, the protein with V225A 
mutation showed no inhibitory effect on exon 4 inclusion (lanes 7, 8). 
The proteins with mutations introduced in RRM3 and RRM4 (L-V402K-L405D-
L558K-L559D and L-V402K-L405D-L558K-L559D) did not repress splicing of exon 
4 (Fig. 3.22E). Addition of 300 ng of each protein did not change the level of exon 
inclusion (lanes 4, 6), 88% of exon inclusion for both proteins compared to hnRNP 
L-depleted nuclear extract was detected (lane 2). 
Taken together, these data clearly demonstrate that all four RRMs are necessary 
for hnRNP L function in alternative splicing regulation. 
 
A 
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Figure 3.22 SLC2A2 pre-mRNA splicing modulated by hnRNP L and its mutant derivatives. 
(A) HnRNP L protein was selectively depleted from HeLa nuclear extract via biotin pull-down with 
(CA)32 RNA oligonucleotide, the depletion was analysed by Western blotting with an hnRNP L-
specific monoclonal antibody (4D11). Lane 1, untreated extract; lane 2, hnRNP L-depleted extract; 
lane 3, protein eluted from neutravidin beads. GAPDH detection was used as internal standard. (B, 
C, D, E) In vitro splicing of SLC2A2 pre-mRNA in mock-depleted nuclear extract (lane 1), hnRNP L-
depleted nuclear extract (lane 2) or in the presence of increasing amounts (indicated above the gels 
in nanograms) of indicated recombinant hnRNP L wild-type or mutant proteins. 
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Figure 3.23 summarises the RNA binding and alternative splicing activities obtained 
with the different proteins. 
 
Figure 3.23 Summary of the activities of hnRNP L mutant proteins. 
Structures of the full-length and variant proteins are shown schematically at left. The RRMs, the 
glycine- and proline-rich regions are indicated by green, orange and blue boxes, respectively. 
Relative specific activities for high-affinity binding to different substrates and repression activity in 
alternative splicing are indicated by + and – signs. See Figures 3.10 and 3.22 for data used in 
scoring these values. 
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4. Discussion 
 
 
A common feature of many RNA-binding proteins in the RRM family as well as in 
the family of double-stranded RNA-binding proteins and RNA-binding proteins 
containing RGG repeats and KH domains is the presence of multiple RNA-binding 
domains (Kiledjian et al., 1999; Birney et al., 1993; Burd and Dreyfuss, 1994; 
Kharrat et al., 1995; Musco et al., 1996; Maris et al., 2005). Since proteins contain 
one to four RNA-binding domains, an intriguing question is what is the function of 
multiple RNA-binding domains? 
My PhD work was aimed towards understanding the contribution of individual RRM 
domains of hnRNP L and hnRNP LL proteins to their functions. 
For this purpose, I generated hnRNP L and hnRNP LL deletion derivatives and 
variants with amino acid substitutions to study their activities in RNA binding and 
alternative splicing regulation. 
 
 
4.1 Function of multiple RRMs of the hnRNP L and hnRNP LL 
proteins in RNA binding 
 
In some RNA-binding proteins with two or more RRMs, a subset of one or more 
RRM-containing regions is generally sufficient for RNA binding (Burd et al., 1991; 
Chung et al., 1996; Dember et al., 1996; Sachs et al., 1987). Some other RNA-
binding proteins do require all of their RRMs for RNA-binding activity (Green et al., 
1992; Zamore et al., 1992). 
EMSA and filter binding assay results with hnRNP L deletion derivatives 
(summarised in Fig. 3.10) demonstrate that the combination of at least two RRMs 
(1/2 or 2/3) is necessary and sufficient for high-affinity binding of hnRNP L to CA-
repeat RNA. In comparison, the C-terminal RRMs 3 and 4 do not show detectable 
association with CA-repeat RNA. 
Interestingly, the binding of hnRNP L to CA-repeat RNA with a nanomolar affinity is 
achieved only in the presence of RRM2 with at least one additional RRM. A similar 
phenomenon is observed with many other multi-RRM proteins. For example, in Sxl1 
(Samuels et al., 1998), hnRNP A1 (Shamoo et al., 1994), poly(A)-binding protein 
(Burd et al., 1991), nucleolin (Serin et al., 1997), ASF/SF2 (Caceres and Kreiner, 
1993), and U2AF (Zamore et al., 1992), binding by a single RRM is much weaker 
and/or less specific than binding by a combination of two or more RRMs. 
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In contrast to CA-repeat RNA, the high-affinity recognition of CA-rich RNA required 
the entire hnRNP L protein and deletion mutant proteins containing only two RRMs 
fail to stably associate with the RNA. 
RNA-binding proteins in general, besides their RNA-binding domains, contain other 
domains that are termed auxiliary domains. The functional significance of auxiliary 
domains is a relatively unexplored area; for example, these regions may mediate 
protein-protein interactions and localise the protein within the cell. HnRNP L has the 
glycine- and proline-rich regions. Deletion of the N-terminal glycine-rich region had 
no effect on RNA binding to CA-repeat and CA-rich RNAs, indicating that the 
glycine-rich region is not necessary for RNA binding. It might have some other 
function, for example, nuclear localisation of hnRNP L, since the nuclear 
localisation signal locates within a glycine-rich region (Taguchi et al., 2004). 
Substitution of Val104 in the RRM1, Val225 and Gly231/Met235 in the RRM2 of 
hnRNP L did not significantly reduce the binding activity of the full-length protein to 
CA-repeat and CA-rich RNAs. These amino acid residues are not the major 
determinants of general RRM-mediated RNA binding or the introduced mutations 
are compensated by binding of other intact RRMs. 
Interestingly, the inter-domain interaction between hnRNP L RRM3 and RRM4 
(Skrisovska and Allain, 2008) which has been disrupted by several amino acid 
substitutions affected only binding to CA-rich RNA, indicating that tight interaction of 
hnRNP L RRM3 and RRM4 is important for recognition of high-score binding motifs 
spread over the RNA substrate. The structure analysis of two PTB domains RRM3 
and RRM4 (RRM3-4) revealed a very unusual interaction between these two RRMs 
and also a new role for the inter-domain linker (Vitali et al., 2006). The structure 
determination of PTB RRM3-4 in its free and RNA bound states revealed that 
RRM3 and RRM4 are interacting in both states, but a single difference in structures 
lies in a small region of the inter-domain linker. This region is unstructured in the 
free RRM3-4 and becomes structured upon RNA binding, forming a short α-helix, 
which is significantly involved in RNA binding (Vitali et al., 2006). Sequence 
alignment of human PTB and hnRNP L shows that the inter-domain contact and the 
resulting structure of RRM3 and RRM4 are very likely conserved between these 
two proteins. 
EMSA results for hnRNP LL protein indicate that for high-affinity binding to CA-
repeat and CA-rich RNAs all four RRMs are required, since deletion derivatives 
LL∆C (RRMs 1 and 2), LL∆N (RRMs 3 and 4) and LL162-429 (RRMs 2 and 3) 
demonstrate no binding activity. 
HnRNP L and hnRNP LL have 58% overall protein sequence identity and are 
similar in size. The RNA-binding domains in these proteins are particularly 
conserved, however, there are some divergent residues in these domains that may 
account   for   the  differential  sensitivity  of  hnRNP L and hnRNP LL  to  the tested  
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CA-repeat and CA-rich RNAs. Furthermore, the glycine- and proline-rich regions, 
which are less pronounced and absent in hnRNP LL, respectively, may be 
important for function and/or fine tuning of the binding specificity. 
 
4.2 Role of RRM2 in RNA-binding activity of hnRNP L 
 
From the analysis of the binding behaviour of the two hnRNP L deletion constructs, 
L∆C (RRMs 1 and 2) and L173-502 (RRMs 2 and 3), it might be concluded that 
RRM2 represents the domain required for sequence specific RNA recognition, 
whereas RRM1 and RRM 3 probably contribute to stabilisation of the binding (Fig. 
3.6). The important role of hnRNP L RRM2 in RNA binding was confirmed by the 
introduction of point mutations in RRM2 in the context of two-RRM derivatives (Fig. 
3.4). Mutant proteins with inactivated RNA-binding activity of RRM2 did not 
associate with CA-repeat RNA, confirming that RRM2 is the major determinant for 
RNA-binding affinity and specificity. However, other domains of hnRNP L besides 
RRM2 are also needed for sequence specific recognition since it appears that 
RRM2 alone can not efficiently bind to RNA. Thus, RRM2 may be sufficient to 
generate RNA-binding sequence-specificity, but additional RRMs are required for 
stabilisation of the formed complex. This is consistent with the fact that the full-
length protein shows the highest binding affinity, and may provide a mechanistic 
explanation for the observation that deletion mutant proteins show reduced binding 
affinity compared to full-length hnRNP L. 
Sequence comparison revealed that human hnRNP L shares significant homology 
(55% similarity, 29% identity) with PTB. Moreover, both proteins contain four RRMs 
in which sequence identity reaches 32%. However, the substrate specificity of 
hnRNP L was not changed upon mutation of important for substrate specificity 
amino acid residue valine in RRM2 to isoleucine, present in PTB at the same 
position (Fig. 3.8). 
 
4.3 CA-rich elements: important features for high-affinity binding 
of hnRNP L 
 
My data demonstrate that hnRNP L binds tightly and specifically to CA-rich RNA, 
such as GSTZ1 or CA-rich cluster. The binding of hnRNP L to CA-rich cluster within 
its own pre-mRNA has been shown to be important for autoregulation of hnRNP L 
protein expression in HeLa cells (Rossbach et al., 2009). A highly conserved CA-
rich cluster is a dense cluster of high-score hnRNP L binding motifs extending over 
800   nucleotides   and   bound   by   more  then  one  molecule  of  hnRNP  L  in  a  
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cooperative manner. Detailed study of CA-rich cluster indicates that for high-affinity 
binding of hnRNP L several high-score binding motifs are necessary. Moreover they 
have to be separated by a spacer of 7-10 nucleotides (Fig. 3.15 and 3.18). These 
data demonstrate that hnRNP L, probably, binds RNA via multiple RRM domains, 
each of which independently recognise different high-score binding motifs on the 
RNA. This observation is in agreement with previously obtained results indicating 
that the presence of all four RRMs provides highest binding affinity. 
Structure analysis of RRM domains in complex with RNA have demonstrated that a 
single RRM can accommodate between two to eight nucleotides (Mazza et al., 
2002; Price et al., 1998; Calero et al., 2002). In addition, the structures of several 
tandem RRMs bound to RNA have been determined. In most cases (Deo et al., 
1999; Handa et al., 1999; Johansson et al., 2004; Wang and Tanaka-Hall, 2001; 
Allain et al., 2000), both RRM domains are separated by a small linker and 
recognise two adjacent stretches within the same RNA molecule. This topology 
provides a large RNA-binding surface. However, there are exceptions, for example 
RRMs 3 and 4 of PTB (Oberstrass et al., 2005; Vitali et al., 2006).  The tandem 
RRMs make intensive inter-domain contact and their RNA-binding surfaces point 
away from each other. This topology prevents the two domains from binding 
adjacent sequences within a single RNA, but instead favours looping of RNA if the 
two binding sites are separated by at least 15 nucleotides (Oberstrass et al., 2005). 
 
4.4 HnRNP L working model  
 
To summarise the RNA-binding data presented in this work, the current working 
model of hnRNP L binding activity is proposed in Figure 4.1. As shown, the hnRNP 
L protein contains four RRMs, where RRM1 and RRM2 act, probably, 
independently of each other, and RRM3 and RRM4 are tightly associated with each 
other. Two types of RNA substrates might be recognised by hnRNP L: CA-repeat 
and CA-rich RNAs. High-affinity binding to CA-repeat RNA requires the combination 
of two RRMs (1/2 and 2/3), however, presence of all four RRMs stabilise the 
interaction to a greater extend. For high-affinity recognition of CA-rich RNA the full-
length protein is necessary. 
The RRMs of hnRNP L are connected by linkers of variable length. The ability of 
the protein to recognise a specific RNA depends on the linker length and its rigidity. 
CA-repeat RNA is more adoptable for recognition by hnRNP L and the lengths of 
the inter-domain linkers are not very important. CA-rich RNA carries high-score 
binding motifs separated by spacers. A long linker sequence between two RRMs 
(e.g. between  2  and  3)  allows  the  two  domains   to   recognise   binding   motifs  
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separated by a spacer of a varying length, whereas a short linker (e.g. between 1 
and 2) pre-disposes the domains to bind to adjacent motifs. 
The binding of RRM4 to RNA was determined by NMR spectroscopy study of 
RRM4-RNA complex (personal communication with Prof. Allain, Zurich). Thus, the 
inter-domain interaction between RRM3 and RRM4 might induce the formation of 
RNA loop or might be involved in functionally important homodimerisation or 
interaction with other splicing factors. 
CACACACACACACACACACACACACACACACACACACACACACACACACACACACACACA
RRM1 RRM3
RRM4
RRM2
RRM1
CACA
RRM2
CACA
RRM3
RRM4
CACA
CACA
RRM2
CACA
RRM3
RRM4
CACA
RRM1
OR
CA
CA
 
 
Figure 4.1 Model illustrating the interaction of hnRNP L with different RNA substrates. 
The RNA-binding protein hnRNP L contains four RRMs (blue pentagon). Each RRM interacts with a 
single high-score binding motif (CACA) within the same RNA. The high-affinity binding to CA-repeat 
RNA is not restricted by the length of the inter-domain linkers due to the presence of a large number 
of possible binding sites. In the case of CA-rich sequences, the RNA should meet the spatial 
requirements such as the length of the spacers between high-score binding sites to allow high-
affinity binding of hnRNP L. The C-terminal domains RRM3 and RRM4 might be involved either in 
RNA looping or interaction with other splicing factors or homodimerisation of hnRNP L. 
 
4.5 HnRNP L interacts with hnRNP LL 
 
Heterogeneous nuclear ribonucleoproteins (hnRNPs), being very abundant and 
avid RNA-binding proteins, play an important role in several RNA-related biological 
processes such as transcription, pre-mRNA processing, mature mRNA transport to 
cytoplasm and translation. These diverse functional properties can be achieved not 
only through RNA  binding,  but can also be powerfully modified by a protein-protein  
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interaction with other factors (Kim et al., 2000; Hahm et al., 1998a; Scherly et al., 
1990; D’Ambrogio et al., 2009). 
Many interaction partners defining the hnRNP L function were identified in the past. 
The interaction with human AP-endonuclease 1 identified a novel function of 
hnRNP L in transcriptional regulation (Kuninger et al., 2002), interaction of hnRNP L 
with hnRNP D/AUF1 function in the export of mRNA from nucleus to cytoplasm, 
mRNA turnover and the translation of a certain mRNA (Park et al., 2007). As a 
component of SLM/Sam68 nuclear bodies hnRNP L is involved in coupling 
signalling and splicing (Rajan et al., 2009), as an adopter for TAP and Aly/REF 
proteins binding of hnRNP L enhances nucleocytoplasmic export of PPE-containing 
intronless RNAs (Guang et al., 2005; Liu and Mertz 1995), interaction between 
hnRNP L and PTB plays an important role in positive regulation of Cat-1 translation 
via IRES that causes a global decrease in protein synthesis under stress conditions 
(Majumder et al., 2009). HhRNP L as a component of human KMT3a complex 
contributes to H3K36 trimethylation indicating a new function of hnRNP L in 
chromatin modification (Yuan et al., 2009). 
In my work I identified that hnRNP L specifically interacts with its paralog hnRNP LL 
in vitro (Fig. 3.20). The interaction was mapped, indicating the regions of both 
proteins involved in protein-protein interaction. HnRNP L shows presence of 
multiple interactions sites, suggesting that protein-protein interaction can occur 
through different parts of the protein. In contrast, for hnRNP LL I could demonstrate 
that only the N-terminal domains (RRMs 3 and 4) are required for interaction with 
hnRNP L. 
Considering my results and reported functions of hnRNP L and hnRNP LL, it is 
possible to speculate about the role for the hnRNP L-LL interaction. Previously, only 
splicing regulatory function of hnRNP LL has been reported: it is an essential 
regulator of CD45 splicing in activated T-cells (Topp et al., 2008; Wu et al., 2008; 
Oberdoerffer et al., 2008), whereas several functions have been documented for 
hnRNP L, including pre-mRNA splicing, mRNA polyadenylation, export, translation, 
and stability (Hahm et al., 1998b; Shih and Claffey 1999; Hiu et al., 2003; Hung et 
al., 2008; Tong et al., 2005). The hnRNP L-LL complex may combine these 
activities and perform different functions. Taking into account that hnRNP LL is a 
tissue-specific protein, its expression is up-regulated in blood cells and testis, and 
the hnRNP L-LL interaction may have a tissue-specific role. Due to the presence of 
multiple interaction domains the hnRNP L-LL complex may simultaneously interact 
with other factors to form multiple protein or protein-RNA complexes. It is further 
plausible that the interaction of hnRNP L-LL with one of their partners (protein and 
RNA) may serve to regulate the interaction with another partner. 
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4.6 HnRNP L cooperatively binds to CA-rich cluster to activate 
hnRNP L exon 6a inclusion 
 
It was discovered that hnRNP L autoregulates its own expression on the level of 
alternative splicing, using a highly conserved CA-rich cluster spread over 800 
nucleotides of intron 6. If included, exon 6A introduces a premature termination 
codon, resulting in NMD and downregulation of hnRNP L mRNA level (Rossbach et 
al., 2009). I demonstrated here that hnRNP L binds with high affinity and specificity 
to both parts of the CA cluster (Fig. 3.12). Moreover, EMSA and glycerol gradient 
centrifugation results show that the binding of hnRNP L molecules to the CA-rich 
cluster occurs in a strong cooperative manner (Fig. 3.13; 3.14). 
Cooperative binding of hnRNP L to multiple high-score binding sites on its own pre-
mRNA raises several possibilities as how the autoregulation of splicing might be 
achieved. This is a very critical biological step, since autoregulation may be 
important to prevent abnormally high levels of hnRNP L, which could lead to 
inappropriate processing of multiple targets. First, cooperative multiple binding 
could provide additive binding strength, which might simply be required for specific 
interaction between hnRNP L and CA-rich cluster of intron 6. Second, cooperative 
interaction of multiple hnRNP L molecules may facilitate binding to low-score 
binding motifs between high-score binding motifs to make such a region more 
accessible for splicing factors and spliceosome assembly. Third, cooperativity could 
also result in a faster response to increased level of hnRNP L proteins. In this case, 
the switch between two splicing modes could be set in a reliable way such that a 
threshold level of hnRNP L protein is both necessary and sufficient for selection of 
exon 6A inclusion. The autoregulatory feedback mechanism would contribute to 
hnRNP L active homeostasis. 
My gel filtration results demonstrate that hnRNP L exists in solution under RNA-free 
conditions in monomeric and dimeric forms (Fig. 3.19).  Thus, hnRNP L monomers 
or dimers could bind to each pair of CA elements. These initial interactions may 
then assemble into a stable higher order structure, resulting in an exon 6A exposed 
for spliceosome assembly. 
In addition, I could show that hnRNP L’s paralog hnRNP LL also binds to the CA-
rich cluster of hnRNP L pre-mRNA with high affinity and specificity (Fig. 3.12).  
Previously, we could demonstrate a cross-regulatory mechanism explaining the 
reciprocal regulation of the two proteins (Rossbach et al., 2009). It was shown that 
hnRNP L regulates not only its own expression but also the expression of hnRNP 
LL protein by inclusion of a similar “poison exon” into the pre-mRNA of hnRNP LL. 
The binding of hnRNP LL to hnRNP L pre-mRNA raises the question whether 
hnRNP LL could cross-regulate the expression of hnRNP L. Since nuclear hnRNP L  
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protein levels are more than 10-fold higher than those of hnRNP LL (Hung et al., 
2008), it is more meaningful to test this hypothesis in cell lines or in certain tissues 
where the protein level of hnRNP LL is up-regulated, for example T lymphocytes 
(Oberdoerffer et al., 2008; Topp et al., 2008). 
 
 
4.7 Function of multiple RRMs in alternative splicing regulation 
 
HnRNP L was identified as a global and versatile regulatory protein in the human 
system with roles in alterative splicing (Hung et al., 2008). HnRNP L has been 
shown to act either as a repressor or as an activator of alternative splicing 
depending on the location of its binding sites (Hui et al., 2005). One of the well-
characterised target genes of hnRNP L is the SLC2A2 gene (Heiner et al., 2010). It 
was demonstrated that if hnRNP L binds to the CA-repeat sequence close to the 5’ 
splice site of the alternative exon 4 recruitment of the U1 snRNP is impaired 
resulting in exon 4 skipping. 
Here I have investigated the function of the different domains of hnRNP L in the 
regulation of alternative splicing, namely repression of alternative exon 4 inclusion 
of a SLC2A2 minigene construct. The aim of this study was to determine whether 
specific domains of hnRNP L are necessary for the splicing repressor activity of the 
protein. 
Splicing complementation assays confirmed that alternative splicing of SLC2A2 is 
effectively regulated by full-length hnRNP L as well as by L∆G protein (Fig. 3.22B), 
indicating that the glycine-rich region  is not required for splicing repression. 
Deletion mutant proteins L∆C (RRMs 1 and 2) and L∆N (RRMs 3 and 4) did not 
restore the inhibitory function on exon inclusion (Fig. 3.22C). These findings 
suggest that high-affinity binding of L∆C protein to CA-repeat RNA is not sufficient 
for regulation of alternative splicing. Due to the absence of two N-terminal RRMs 
the functionally important homodimerisation or interaction with other splicing factors 
might fail and the L∆C protein is unable to regulate exon repression. 
The contribution of all four RRMs in alternative splicing regulation was confirmed 
using mutant proteins with amino acid substitutions in RRM1 and RRM2 (Fig. 
3.22D) in splicing complementation assays.  These proteins did not abolish the 
alternative splicing activity of hnRNP L, except for the mutation at position 225 in 
RRM2, although the point mutations resulted in reduced binding affinity to CA-
repeat RNA. 
It was shown before that RRM3 and RRM4 of hnRNP L make intensive inter-
domain contacts (Skrisovska and Allain, 2008) and that this interaction is important 
for their RNA-binding  activity (Fig. 3.10).  Analysis  of alternative  splicing activity of  
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hnRNP L indicates that the repressor function of the protein was abolished upon the 
disruption of the inter-domain interaction between these two domains (Fig. 3.22E). 
Previously, the important role of the inter-domain interaction between RRM3 and 
RRM4 in splicing regulation was shown for PTB protein (homolog of hnRNP L). 
Deletion of the entire RRM4 or the 12 amino acid region of RRM4 abolished the 
repression activity of PTB (Haiyng et al., 2002). Later the 12 amino acid region was 
mapped by NMR spectroscopy as a part of an unusually large inter-domain 
interface between RRM3 and RRM4 (Vitali et al., 2006), demonstrating that 
disruption of the interaction had an effect on splicing activity of PTB. 
 
 
4.8 Perspectives 
 
The structural study of hnRNP L and hnRNP LL in their free and RNA bound states 
will help to gain insight into the protein’s three-dimensional structure, providing a 
detailed knowledge about the organisation of the proteins’ RRMs. The structural 
analysis of the RNA-protein complex will reveal the basis for sequence-specific 
recognition of singe-stranded RNA, high-affinity binding of hnRNP L and hnRNP LL 
to certain RNA sequences, and functional synergy between the RRMs. 
The sequence specificity of hnRNP L appears to be similar for RNA and ssDNA 
(data not shown). The three-dimensional study of hnRNP L in complex with either 
RNA or ssDNA will give information about differences in binding to these 
substrates. 
The inter-RRM linker is highly conserved in length and sequence and has been 
implicated in RNA binding and alternative splicing regulation (Burd at al., 1994; 
Mayeda et al. 1998). The structure analysis of hnRNP L will demonstrate whether 
the linker segment carrying the glycine- and proline-rich regions are directly 
involved in both protein–protein and protein–RNA interactions. 
Further studies should aim to identify the interaction partners for hnRNP L that are 
required for regulation of splicing activity of the protein. The study with the deletion 
mutants should be continued to identify the mechanism and the regions of the 
hnRNP L protein involved in homodimerisation and cooperative binding. For many 
proteins, for example PTB, multimerisation and cooperative binding to target RNAs 
are functionally important. The zone of repression formed by PTB through 
multimerisation across an alternative exon or between binding sites flanking an 
alternative exon is one of the mechanisms of splicing regulation (Wagner at al., 
2001; Auweter at al., 2008). 
Number of studies should be done to identify the post-transcriptional modifications 
of hnRNP L and hnRNP LL proteins and  the role  of  such modifications  in splicing  
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regulation. It has been shown that pre-mRNA splicing, as well as other biological 
processes, can be regulated both positively and negatively by reversible protein 
phosphorylation (Mermoud et al., 1994). For example, the function of hnRNP C 
proteins in pre-spliceosome assembly is coupled to dynamic cycle of their 
phosphorylation and dephosphorylation (Mayrand et al., 1993). It has been shown 
that hnRNP A1 accumulates in cytoplasm upon its phosphorylation (Allemand et al., 
2005). The decrease in nuclear levels of hnRNP A1 led to alternative splicing 
changes in an E1A minigene reporter. 
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Abbreviations 
 
oC centigrade 
µg microgram 
µl microliter 
µM micromolar 
A adenosine 
aa amino acid(s) 
APS ammonium persulfate 
ARS activation-responsive sequence 
ATP adenosine triphosphate 
BBP branchpoint binding protein 
bp base bair(s) 
BPS branchpoint sequence 
BSA bovine serum albumin 
C cytidine 
ca. approximately 
Ci Curie 
CBP Cap binding protein 
cDNA complementary DNA 
CLIP in vivo Cross-Linking and ImmunoPrecipitation 
cm centimetre 
cpm counts per minute 
CTP cytidine triphosphate 
DMPC dimetyl pyrocarbonate 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTP deoxynucleoside triphosphate 
DTT dithiothreitol 
E.coli Escherichia coli 
e.g. exempli gratia (=for example) 
ECL enhanced chemiluminiscence 
EDTA ethylenediamine tetraacetic acid 
ESE exonic splicing enhancer 
ESS exonic splicing silencer 
EST expressed sequence tag 
et al. et alii (=and others) 
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FCS fetal calf serum 
g gram 
g acceleration of gravity 
G guanosine 
GST glutathione sulfate transferase 
GTP guanosine triphosphate 
h hour(s) 
HEPES N-2-hydroxyethylpiperazine 
His histidine 
hnRNA heterogeneous nuclear RNA 
hnRNP heterogeneous nuclear ribonucleoprotein 
hnRNP LL hnRNP L-like 
IgG immunoglobulin G 
IPTG isopropyl-1-thio-β-Dgalactoside 
ISE intronic splicing enhancer 
ISRE intronic splicing regulatory element 
ISS intronic splicing silencer 
kb kilobasepair 
KD dissociation constant 
kDa kilodalton 
M molar 
mg milligram 
min minute(s) 
ml milliliter 
mM millimolar 
mmol Millimole 
mRNA messenger RNA 
mut mutant 
N any nucleotide 
ng nanogram 
Ni-NTA nickel-nitrilotriacetic acid 
nm nanometer 
nM nanomolar 
NMD nonsense-mediated decay 
NP-40 nonidet P-40 
nt nucleotide(s) 
NTP ribonucleoside triphosphate 
OD optical density 
PAGE polyacrylamide gel electrophoresis 
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PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PK proteinase K 
pmol picomol 
PMSF phenylmethylsulfonyl fluoride 
Poly(A) polyadenylic acid 
pre-mRNA precursor messenger RNA 
PTB polyprymidine tract binding protein 
PTC premature termination codon 
RBD RNA-binding domain 
RBP RNA-binding protein 
RNA ribonucleic acid 
RNase ribonuclease 
rpm rounds per minute 
RRM RNA recognition motif 
RT reverse transcription 
RT reverse transcriptase 
s second(s) 
SAP shrimp alkaline phosphatase 
SDS sodium dodecyl sulfate 
SELEX systematic evolution of ligands by exponential enrichment 
SF1 splicing factor 1 
SLC2A2 solute carrier family 2 
snRNA small nuclear RNA 
snRNP small nuclear ribonucleoprotein 
SR serine-arginine-rich 
T thymidine 
TJP1  tight junction protein 
tRNA transfer RNA 
U uracil 
U Unit 
U2AF U2 auxiliary factor 
U2AF35 U2AF 35 kDa subunit 
U2AF65 U2AF 65 kDa subunit 
UTR untranslated region 
v/v volume per volume 
w/v weight per volume 
WT wildtype 
Y pyrimidine base 
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